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Beyond "Safe and Effective":
The Role of the Federal Government in Supporting
and Disseminating Comparative-Effectiveness
Research
-MaggieH. Francis*
One of the great successes of the United States health care system has
been its ability to encourage the development of innovative drugs, devices,
and treatments that have dramatically improved the health of Americans.
Through the Food and Drug Administration ("FDA"), the federal
government has played a key role in this process by standardizing and
synthesizing information about innovations, as well as by serving as a
gatekeeper to ensure that only safe and effective drugs and devices enter the
market. Nevertheless, despite the efforts of the FDA and other federal and
state-level government entities to generate and digest information about
medical innovations, this is a task that has so far exceeded the capacity of
the government. As a result, while a tremendous amount of information
exists about both new and existing drugs, therapies, tests and devices
("treatments"), there is very little useful information available comparing
the costs and effectiveness of different options that can be used to treat the
same condition. Furthermore, the private and non-profit sectors have so far
also failed to meet this need.
Nearly everyone agrees that more information comparing the
effectiveness of different medical treatments is important for the future of
the United States health care system. Comparative-effectiveness research
("CER") has the potential to improve health care quality and efficiency
while also decreasing costs. As with many issues in health policy, however,
the consensus surrounding the importance of CER is limited. Proponents of
government investment in CER have faced intense criticism about costs,
implementation, the role of the government in health care, and the potential
slippery-slope consequences of CER. As a result, while 2009 and 2010
were years of unprecedented federal investment in CER, the government's
.*B.A. Boston University, J.D. Harvard Law School. Ms. Francis would like to Peter Barton
Hutt, Lecturer on Law, Harvard Law School.

329

Published by LAW eCommons, 2012

1

Annals of Health Law, Vol. 21 [2012], Iss. 2, Art. 4

330

Annals of Health Law

[Vol. 21

future role in supporting and conducting comparative-effectiveness
information remains uncertain.
This Article addresses the questions of what role the government can and
should play in the generation, dissemination, and use of CER. While some
of the uncertainty surrounding the federal government's recent efforts
derives from the political challenges facing the 2010 health reform law as a
whole, the remainder is associated with difficulties inherent to CER.
Numerous challenges, both technical and political, will make it difficult to
realize the potential benefits of the research in full. Yet even if the
government's recent initiatives are not entirely successful in controlling
health care costs or vastly improving health care quality through more
appropriate use of medical treatments, they represent an important step in
the right direction. Ultimately, the future of the United States health care
system depends on its ability to filter medical innovations not only by their
safety and efficacy, but their relative value in comparison to alternatives.
Government sponsored CER has potential to serve an important role in
accomplishing this objective.
Part I of this Article defines CER and describes the problems that CER
seeks to address, as well as the arguments for and against this type of
research. Part II then briefly summarizes some potential models for
governmental involvement in CER, and provides examples of how the
governments of other countries have supported CER. Part III details the
history of governmental participation in CER, including recent investments
made by the federal government in the American Recovery and
Reinvestment Act of 2009 ("ARRA")' and the Patient Protection and
Affordable Care Act of 2010 ("ACA").2 Lastly, Part IV identifies some
opportunities and challenges associated with these recent investments. It
also provides policy recommendations for, and predictions about, the future
of government involvement in CER. Although some of the loftier
expectations foisted upon the research by its supporters are unlikely to be
realized, the federal government's recent investments in CER have
important potential to both generate valuable information for providers and
consumers3 of health care, and improve the norms and metrics against
1. American Recovery and Reinvestment Act of 2009, Pub. L. No. 111-5, 123 Stat. 115
(2009).
2. Patient Protection and Affordable Care Act of 2010, Pub. L. No. 111-148, 124 Stat.
119 (2010), as amended by the Health Care and Education Reconciliation Act of 2010, Pub.
L. No. 111-152, 124 Stat. 1029 (2010) [hereinafter Reconciliation Act] (following references
to the ACA describe the Act as amended by the Reconciliation Act.).
3. Use of the phrase "health care consumers" has recently faced some criticism.
See,e.g., Paul Krugman, Patients Are Not Consumers, N.Y. TIMES, April 22, 2011, at A3.
My intent is to use the term in a neutral sense, that is, to describe the broad category of
individuals and groups who consume health care services (which is not necessarily identical
to the set of health care "patients"), but without the implication that they subscribe to any
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which medical innovations are assessed.
I. WHAT IS CER?
A. Defining CER
In order to define and understand CER, it is first necessary to identify the
problems that CER has the potential to ameliorate. Commentators both
inside and outside of medicine have grown increasingly frustrated with the
reality that less than half of standard medical treatments are supported by
scientific evidence of effectiveness. One 2009 study, for example, found
that only 11% of current guidelines issued by the American College of
Cardiology and the American Heart Association were supported by the
highest level of evidence (including "multiple randomized trials or metaanalyses").' In addition, many patients in the United States fail to receive
care that is recommended on the basis of scientific evidence.6 CER is part
of a broader movement to remedy this problem by facilitating and
encouraging the use of evidence-based medicine ("EBM").
While there are a number of ways to define CER,7 the ACA defines
"comparative clinical effectiveness research" as "research evaluating and
comparing health outcomes and the clinical effectiveness, risks, and
specific behaviors common to consumers of other goods. It is also not my intention to
downplay the unique characteristics of the market for health care services or the special
nature of the physician-patient relationship.
4. John Donnelly, Health Policy Brief Comparative Effectiveness Research, HEALTH
AFFAIRS 1 (2010), available at http://www.rwjf.org/files/research/70208.pdf. Furthermore,
it is clear that a wide variety of factors unrelated to a treatment's appropriateness influence
the decision-making process of health care providers. See, e.g., Danil V. Makarov et al., The
Association Between Diffusion of the Surgical Robot and Radical Prostatectomy Rates, 49
MED. CARE 333 (2011) (finding hospitals that purchased surgical robots that were very
expensive but only of "marginal benefit" in treating prostate cancer conducted many more
radical prostatectomies than other hospitals, suggesting the existence of "supply induced
demand").
5. Pierluigi Tricoci et al., Scientific Evidence Underlying the ACC/AHA Clinical
PracticeGuidelines, 301 JAMA 831 (2009).
6. Elizabeth A. McGlynn et al., The Quality of Health Care Delivered to Adults in the
United States, 348 NEw ENG. J. MED. 2635, 2635 (2003) (reporting that only 54.9% of a
random sample of adults surveyed in twelve metropolitan areas received recommended
care).
7: For a chart describing how different organizations have defined CER, see COMMITTEE
ON COMPARATIVE EFFECTIVENESS RESEARCH PRIORITIZATION, INSTITUTE OF MEDICINE,
INITIAL NATIONAL PRIORITIES FOR COMPARATIVE EFFECTIVENESS RESEARCH 35-36 (2009)
[hereinafter IOM NATIONAL PRIORITIES FOR CER] (including definitions from the

Congressional Budget Office, the American College of Physicians, the Medicare Payment
Advisory Board, and the Agency for Healthcare Research and Quality, among others); see
also AHRQ Effective Health Care Program, What is Comparative Effectiveness Research,
http://www.effectivehealthcare.ahrq.gov/index.cflm/what-is-comparative-effectivenessresearch 1/ (last visited March 30, 2011).
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benefits of [two] or more medical treatments, services, and items."8 The
statute then goes on to define the relevant "medical treatments, services,
and items" as "health care interventions, protocols for treatment, care
management, and delivery, procedures, medical devices, diagnostic tools,
pharmaceuticals (including drugs and biologics), integrative health
practices, and any other strategies or items being used in the treatment,
management, and diagnosis of, or prevention of illness or injury in,
individuals."9 This Article adopts the ACA definition, rather than, for
example, the definitions created by the Institute of Medicine'o and the
Federal Coordinating Council for Comparative Effectiveness Research" for
the purpose of reports ordered by Congress in ARRA,12 for the sake of
consistency and clarity, as well as because it is the definition that will
govern the Patient-Centered Outcomes Research Institute ("PCORI"), the
federal agency that will coordinate the federal government's substantial
new investments in CER.13
Generally speaking, CER is different from other forms of health research
in three ways: it compares at least two treatments, it analyzes "real-world
outcomes" rather than experimental outcomes or general efficacy, 14 and the
resulting information is useful for a number of decision-makers, such as
8.
9.
10.

ACA § 6301 (to be codified at 42 U.S.C. § (a)(2)).).
Id.
IOM NATIONAL PRIORITIES FOR CER, supra note 7, at 41 (defining CER as "the

generation and synthesis of evidence that compares the benefits and harms of alternative
methods to prevent, diagnose, treat, and monitor a clinical condition or to improve the
delivery of care. The purpose of CER is to assist consumers, clinicians, purchasers, and
policy makers to make informed decisions that will improve health care at both the
individual and population levels.").
11.
FEDERAL COORDINATING COUNCIL FOR COMPARATIVE EFFECTIVENESS RESEARCH,
16 (2009), available at
THE CONGRESS
REPORT TO THE PRESIDENT AND

http://www.hhs.gov/recovery/programs/cer/cerannu
alrpt.pdf ("[CER] is the conduct and synthesis of research comparing the benefits and harms
of different interventions and strategies to prevent, diagnose, treat and monitor health
conditions in 'real world' settings. The purpose of this research is to improve health
outcomes by developing and disseminating evidence-based information to patients,
clinicians, and other decision-makers, responding to their expressed needs, about which
interventions are most effective for which patients under specific circumstances.").
12. Id. at 70; Pub. L. No. 111-5, 123 Stat. 115, Title XIII (2009) ("the Secretary [of
Health and Human Services] shall enter into a contract with the Institute of Medicine . . . to
produce and submit a report to the Congress and the Secretary by not later than June 30,
2009, that includes recommendations on the national priorities for comparative effectiveness
research to be conducted or supported with the funds provided in this paragraph and that
considers input from stakeholders.").
13. See infra Section I11(b)(2).
14. Efficacy differs from effectiveness in that efficacy refers to "the effective of the
treatment under optimal conditions" while effectiveness addresses the treatment's effects "in
routine clinical practice."

GRETCHEN A. JACOBSON, CONGRESSIONAL RESEARCH SERVICE,

COMPARATIVE CLINICAL EFFECTIVENESS AND COST-EFFECTIVENESS RESEARCH:BACKGROUND,

HISTORY AND OVERVIEW 4-5 (2007).
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health care providers, consumers, and policymakers (as opposed to, for
example, just safety regulators). 5 Although CER is helpful in a number of
contexts outside of medical treatment, such as public health,16 health
policy," and health system design,' 8 this Article focuses on the use of CER
to study medical treatments.
However, many of the challenges,
opportunities, and ideas discussed here are applicable in other contexts as
well.
B. Arguments Against and in Favor of CER
Although the idea of increasing the amount of comparative information
available for health care providers and consumers is intuitively appealing
and the broader EBM movement has gained popularity in recent years,
proponents of CER have thus far faced an uphill battle.19 First, would-be
users of CER have found that comparative-effectiveness information is not
always available,2 0 and even if evidence is available, it may be inadequate
to provide a complete picture about how a treatment works in the real
15. Louis P. Garrison Jr. et al., A Flexible Approach To Evidentiary Standards for
ComparativeEffectiveness Research, 29 HEALTH AFF. 1812, 1813 (2010).
16. Kevin G. Volpp & Anup Das, Comparative Effectiveness - Thinking beyond
Medication A versus Medication B, 361 NEW ENG. J. MED. 331 (2009) (calling for CER that
measures the effectiveness of medical treatments against behavioral and health system
interventions); see also G. Caleb Alexander & Randall S. Stafford, Does Comparative
Effectiveness Have a Comparative Edge, 301 JAMA 2488, 2489 (2009) (calling for
comparisons of strategies involving patient behavior or non-physician initiated treatments,
such as alternative therapies); See generally, e.g., Steven M. Teutsch & Jonathan E. Fielding,
Applying Comparative Effectiveness Research To Public and Population Health Initiatives,
30 HEALTH AFF. 349 (2011) (advocating for the application of CER to population-level
social and environmental determinants of health and discussing the similarities and
differences between this type of CER and CER on individual-level medical treatments).
17. MARK MCCLELLAN & JOSHUA BENNER, BROOKINGS INST., COMPARATIVE
EFFECTIVENESS RESEARCH: WILL IT BEND THE HEALTH CARE COST CURVE AND IMPROVE
QUALITY?, 1, 8 (2009), availableat http://www.brookings.edu/events/2009/0609 health
care cer.aspx (calling for CER on different policies that influence provider adoption of
different treatments).
18. See Atul Gawande, The Cost Conundrum, THE NEW YORKER, June 1, 2009, at 36, 44
("Congress has provided vital funding for research that compares the effectiveness of
different treatments, and this should help reduce uncertainty about which treatments are best.
But we also need to fund research that compares the effectiveness of different systems of
care-to reduce our uncertainty about which systems work best for communities.").
19. Dan Mendelson & Tanisha V. Carino, Evidence-Based Medicine In The United
States - De Rigueur Or Dream Deferred?, 24 HEALTH AFF. 133, 133 (2005) ("All clinicians
and managed care plans believe that their decisions are based on evidence . . . . However ...

there is little evidence of EBM's success in influencing behavior and as a well-accepted
foundation for how patient care should be organized, delivered, and financed.").
20. For example, because the FDA does not regulate medical or surgical treatments, less
information about safety and efficacy is available for those treatments in comparison to
drugs and devices. See Lynn M. Etheredge, A Rapid-Learning Health System, 26 HEALTH
AFF. w107, w 112 (2007).
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world.2 1 While this problem will decrease as researchers complete more
CER studies, some "residual uncertainty" remains inevitable, raising
difficult questions about when scientific evidence is strong enough to
justify alteration of the behavior of health care providers. 22
Second, it can take a long time for new information about treatments to
diffuse among vast networks of health care providers, if such diffusion ever
occurs. 23 The Institute of Medicine ("IOM") estimates that it takes, on
average, 17 years for physicians to broadly adopt a treatment found to be
more effective than alternatives.24 This issue is related to a number of
separate problems. A non-exhaustive list includes that the designers of
clinical trials often fail to plan for dissemination of the studies' results,
information distributed in continuing medical education programs may be
strongly influenced by industry biases, and industry marketing typically
favors the use of expensive products regardless of comparativeeffectiveness evidence.25 In addition, some health care providers may resist
adopting new practices for practical 26 or cultural 27 reasons, a problem
exacerbated by the reality that most health care providers are not subject to
quality controls requiring them to make use of current research.28
A third and related point is that popular culture does not always praise
21. Id. at will (noting that, particularly for drugs, it can be difficult to determine the
efficacy of a treatment based on clinical trials alone, and sometimes important safety or
efficacy information is only available once a drug has been used by a number of patients
over a long period of time); Norbert Gleicher, 'Expert Panels' Won't Improve Health Care,
WALL ST. J., Oct. 18, 2009, at A21; Jerome Groopman & Pamela Hartzband, Why 'Quality'
Care Is Dangerous, WALL ST. J., April 8, 2009, at Al3 (noting that sometimes scientific
evidence about a treatment turns out to be wrong). At the same time, there are costs to
waiting for better information to adopt a new treatment, see generally Kalipso Chalkidou et
al. Evidence-Based Decision Making: When Should We Wait For More Information?, 27
HEALTH AFF. 1642, 1642-1644 (2008).

22. See generally Karl Claxton et al., When Is Evidence Sufficient?, 24 HEALTH AFF. 93
(2005).
23. See Alexander & Stafford, supra note 16, at 2488-89; see generally Jerry Avorn &
Michael Fischer, 'Bench To Behavior': Translating Comparative Effectiveness Research
Into Improved Clinical Practice,29 HEALTH AFF. 1891 (2010) ("Vaccination against polio,
the concept that mid-to-moderate hypertension requires treatment, the use of statins to
prevent cardiovascular events, the administration of antibiotics near the time of surgery - all
are interventions for which having clear evidence in the medical literature was not adequate
in itself to consistently transform practice on a large scale.").
24. ANN C. GREINER & ELISA KNEBEL, INSTITUTE OF MEDICINE, HEALTH PROFESSIONS
EDUCATION: A BRIDGE TO QUALITY, 33 (2003).
25. Avom & Fisher, supra note 23 at 1892-1894.
26. Id. at 1894-1985 (noting that physicians may be particularly likely resist adoption of
revenue-decreasing new practices, but may also resist adoption due to conceptual objections
to EBM).
27. See Barron H. Lerner, Are Doctors Too Quick to Cut?: Where Culture Comes In,
N.Y. TIMES (Feb. 9, 2011, 05:18 PM), http://www.nytimes.com/roomfordebate/2011/02/09
/are-doctors-too-quick-to-cut/where-culture-comes-in.
28. Avorn & Fisher, supranote 23, at 1895.
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health care providers who invest the time, resources, and energy to adopt
EBM. An undoubtedly exaggerated example of this dynamic can be seen in
the popular television show "House," about an egocentric but brilliant
physician who seems to base diagnostic and treatment decision on intuition,
mostly to the exclusion of considerations based on scientific evidence,
treatment guidelines, and cost.2 9 While the vast majority of people probably
would prefer that their real health care providers not exhibit the same
behaviors as the fictional doctors they watch on television, the ideal of the
renegade doctor acting on the basis of individual judgment and experience
rather than evidence-based guidelines is not limited to entertainment.
Strong political opposition to EBM and CER often references the
importance of resisting "cookbook medicine."30 Because, in its strongest
form, EBM narrows the range of permissible choices available to health
care providers, it threatens the autonomy and discretion otherwise inherent
to the work of professionals. 3' Opponents of CER have also cited concerns
that EBM has potential to limit consumer autonomy by undervaluing
patient preferences.32
Another important argument against CER involves potential conflicts
with the movement toward personalized medicine. Personalized medicine
seeks to identify how genetics influence the different levels of effectiveness
experienced by subpopulations for a single treatment.3 3 Opponents believe
that CER will result in one-size-fits-all medicine that inhibits the growth of
a more granulated approach to patient care. A related concern is that once
researchers have generated CER, the research will be applied equally to
29. See Steven Pearlstein, Self-Help for the Health-Care System, WASH. PosT, June 17,
2009, availableat http://www.washingtonpost.com/wp-dyn/content/article/2009/06/16/AR
200906160308 1.html; Add It Up: Pricing Out A Visit To TV's 'Dr.House,' NPR (June 9,
2010), http://www.npr.org/templates/story/story.php?storyld=127593663; Vickie Williams,
Why House is the True American Health Care Hero and What To Do About It, CONCURRING
OPINIONS (Oct. 12, 2010, 08:39 PM), http://www.concurringopinions.com/archives/2010/10
/why-house-is-the-true-american-health-care-hero-and-what-to-do-about-it.html.
30. Stefan Timmermans & Aaron Mauck, The Promises And Pitfalls of Evidence-Based
Medicine, 24 HEALTH AFF. 18, 21 (2005) (critics of EBM tend "to see medicine in traditional
terms: It is a 'craft' or 'art,' in which individual expertise and technique are allowed to shine
through and ultimately result in a higher standard of patient care. . . . Instead of
revolutionizing care, EBM therefore threatens to bring about stagnation and bland
uniformity, derogatorily characterized as 'cookbook medicine."').
31. Id. at 23.
32. ELIZABETH DOCTEUR & ROBERT BERENSON, URBAN INST. OF REAL TIME POLICY
ANALYSIS, How WILL COMPARATIVE EFFECTIVENESS RESEARCH AFFECT THE QUALITY OF
HEALTH CARE?, 1, 9 (2010), available at http://www.rwjf.org/files/research/20100218Qs

comparativeeffectiveness.pdf.
33. Robert Epstein & J. Russell Teagarden, Comparative Effectiveness And Personalized
Medicine: Evolving Together Or Apart?, 29 HEALTH AFF. 1783, 1784 (2010); Alan M.
Garber & Sean R. Tunis, Does Comparative-Effectiveness Research Threaten Personalized
Medicine?, 360 NEw ENG. J. MED. 1925 (2009).
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treatments and patients for which it is appropriate and inappropriate. 34
EBM and CER have also faced opposition due to concerns about their
implications for health care "rationing." Although health care is a scarce
resource and some form of rationing is inevitable," critics of CER have
expressed concern that the research will be used to deny insurance coverage
for treatments on the basis of cost-benefit analysis.3 6 In particular, critics
have compared CER efforts in the United States to the British National
Institute for Health and Clinical Excellence ("NICE"),37 an agency that both
compiles scientific and cost-effectiveness evidence about medical
treatments and makes coverage recommendations to the country's National
Health Services ("NHS")." This political argument against CER is likely
augmented by the reality that EBM is not a well-understood concept among
the public, and the general population may have some unrealistic beliefs
about physician adoption of scientific research and other issues related to
health care quality. 39
34. See Jerome Groopman, Health Care: Who Knows 'Best'?, N.Y. REV. OF BOOKS
(2010) (noting that some treatments can be standardized, and other treatments must be
tailored to the circumstances of individual patients).
35. Doyle McManus, Healthcare has Rationing in Abundance, L.A. TIMES, Oct. 11,
2009, available at http://articles.latimes.com/2009/oct/11 /opinion/oe-mcmanusl 1; see also
David 0. Meltzer & Allan S. Detsky, The Real Meaning of Rationing, 304 JAMA 2292,
2293 (2010) (distinguishing health care rationing from other forms of government rationing
because individuals are free to purchase any legal health care services; "rationing" in health
care generally refers to whether insurance will pay for a particular service).
36. See, e.g,, Martin Feldstein, ObamaCareIs All About Rationing, WALL ST. J., Aug.
18, 2009, availableat http://online.wsj.com/article/SB10001424052970204683204574358
233780260914.html ("comparative effectiveness could become the vehicle for deciding
whether each method of treatment provides enough of an improvement in health care to
justify its cost."); see also Jacqueline Fox, The Hidden Role of Cost: Medicare Decisions,
Transparency and Public Trust, 79 U. CIN. L. REv. 1, 31 (2011) (noting that "[g]iven
current problems with hidden rationing in Medicare, CER results are at risk of being
distorted [and] relied upon as scientific support for what are, in truth, political and societal
decisions about healthcare rationing.").
37. Of NICE and Men, WALL ST. J., July 7, 2009, available at
http://online.wsj.com/article/ SB124692973435303415.html; Sen. Tom Coburn, The Health
Bill Is Scary, WALL ST. J., Dec. 16, 2009, available at http://online.wsj.com/article/
SB10001424052748703514404574588842779569168.html ("CER panels have been used as
rationing commissions in other countries such as the U.K., where 15,000 cancer patients die
prematurely every year ... CER panels here could effectively dictate coverage options and
ration care").
38. Nicholas Timmins, The NICE Way OfInfluencing Health Spending: A Conversation
With Sir Michael Rawlins, 28 HEALTH AFF. 1360 (2009) (noting that the overall effect of
NICE has been to increase NHS spending because it usually approves the drugs and
treatments that it reviews); Barry Meier, New Effort Reopens a Medical Minefield, N.Y.
TIMES, May 6, 2009, at Bl, available at http://www.nytimes.com/2009
/05/07/business/07compare.html; see also infra notes 130-137 (section discussing NICE);
see generally ABOUT NICE, http://www.nice.org.uk/aboutnice/ (last visited Mar. 30, 2011).
39. Kristin L. Carman et al., Evidence That Consumers Are Skeptical About EvidenceBasedHealth Care, 29 HEALTH AFF. 1400 (2010) (finding that health care consumers tend to
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Even if the rationing consequences of CER are less severe than the
explicit rationing that occurs in the NHS, observers have noted that the
mistakes and biases to which all research, including CER, is prone can have
particularly harmful consequences when providers are incentivized or
coerced into implementing the findings of relatively new research.40 This is
not a trivial concern. Scientific evidence, in medicine or otherwise, is far
from absolute, and the history of medicine is replete with examples where
new evidence has reversed recommendations about formerly well-accepted
treatments. 4 1 Thus, to the extent that aggressive CER promotion results in
more rapid adoption of new or different treatments, it has potential to
increase the harm that occurs when later research discovers unanticipated
side effects or effectiveness problems.
A related concern is that EBM inherently favors existing treatments,
which have had time to be studied, over new treatments, fostering a sort of
status quo bias against medical innovation in the scope of regular patient
care. 42 The counter to this argument is that even outside of formal research,
medical innovation and the testing of new treatments should be systematic
and purposeful, rather than a post-hoc justification for the default position
when scientific evidence about an existing treatment does not exist, or
existing research is not widely disseminated. Regardless, if EMB and CER
result in a medical culture fearful of innovative treatments applied in a non-

believe that newer and costlier care is of higher quality, more care is better care; also noting
that "[t]o the extent that consumers perceive that the application of comparative
effectiveness research to decision making could limit their choice of providers,
inappropriately interfere with physicians' recommendations for treatment, or appear to
'ration' care based on cost, these efforts will encounter consumer resistance and could lead
to a broad consumer backlash.").
40. Groopman, supra note 34 (noting that researchers are susceptible to (1) falling "in
love" with their own research, (2) "confirmation bias," and (3) "focusing illusion," i.e.
predicting exaggerated and unrealistic results).
41. Id. ("For example, Medicare specified that it was a 'best practice' to tightly control
blood sugar levels in critically ill patients in intensive care. That measure of quality was not
only shown to be wrong but resulted in a higher likelihood of death when compared to
measures allowing a more flexible treatment and higher blood sugar."); see also Groopman
and Hartzband, supra note 21; see also Gail Collins, Medicine on the Move, N.Y. TIMES,
April 7, 2011, at A27 ("We got word this week that estrogen therapy, which was bad, is
good again. Possibly. In some cases. This was not quite as confusing as the news last year
that calcium supplements, which used to be very good, are now possibly bad. Although
maybe not. And the jury's still out.. .. We certainly want everyone to keep doing studies.
But it's very difficult to be a civilian in the world of science.").
42. See Patrick L. Taylor, Overseeing Innovative Therapy without Mistaking It for
Research: A Function-BasedModel Based on Old Truths, New Capacities,andLessonsfrom
Stem Cells, 38 J. L. MED. & ETHICS 286, 301 (2010) ("Together with evidence-based
approaches and payer insistence on limiting treatment to accepted practice, the current
environment encourages a defensive crouch: it is safer to avoid innovative therapy and take
refuge in the sanctuary of 'tried and true,' where data in sufficient quantity can be shown to
payers. Taken too far, that will be the death knell of innovative therapy.").
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research setting, they could hinder the development of new therapies.
Because of the possibility that CER will result in insurers refusing to
cover treatments deemed to be comparatively ineffective, some members of
medical treatment industries have also opposed CER.43 Beyond the
argument that CER is problematic simply because it has potential to
decrease revenue for these industries, critics have claimed that CER will
limit health care innovation because it makes investment in innovation
more risky.4 Furthermore, to the extent that CER favors treatments that
have already been the subject of scientific evaluation, CER could also favor
newer, more high-tech treatments over low-tech treatments, such as generic
drugs, traditional treatments, or improvements in health care delivery that
researchers have not rigorously studied.45
Proponents of CER, in contrast, have pointed to a number of important
benefits that could spring from more CER. In addition to the benefits
inherent to having more scientific information available to health care
providers and consumers, such as improved and more transparent
competition in the health care industry46 and fewer geographic disparities in
43. See Jerry Avorn, Debate about Funding Comparative-Effectiveness Research, 360
NEW ENG. J. MED. 1927, 1928 (2009); Uwe E. Reinhardt,'Cost-Effectiveness Analysis' and
US. Health Care, N.Y. TIMEs EcoNoMix BLOG, (Mar. 13, 2009, 06:45 EST),
http://economix.blogs.nytimes.com/2009/03/13/cost-effectiveness-analysis-and-us-healthcare/; Sarah Rubenstein, Drug Makers Talk Up Comparative Effectiveness, Sort Of WALL
ST. J. HEALTH BLOG, (Apr. 14, 2009, 08:51 EST), http://blogs.wsj.com/health/2009/04/14
/drug-makers-talk-up-comparative-effectiveness-sort of/?KEYWORDS comparative+
effectiveness+research (noting that industry support for CER is limited to the extent that the
research is not used to deny insurance coverage for specific treatments).
44. DOCTEUR AND BERENSON, supra note 32, at 9; Diane Suchetka, Cleveland Clinic
CEO Toby Cosgrove Talks About Health-CareReform And More At City Club, CLEVELAND
PLAIN DEALER (Aug. 19, 2010, 10:54am), http://www.cleveland.com/healthfit/index.ssf
/2010/08/clevelandclinic_ceo tobycosg.html ("My concern is that we only pay for
[treatments proven effective by CER], we begin to limit what people are willing to do in
terms of developing new products' [said Cleveland Clinic CEO Toby Cosgrove] . . . 'Right
now, a new heart valve takes 10 years to go from concept to clinical. And it takes 10 years
more to know if it's better than the next heart valve. Now, if I was an investor or if I was a
manufacturer, would I be interested in essentially putting my dollars down not knowing
whether I'm going to get a return on those dollars for 20 years? I think that's a stretch."');
Kalipso Chalkidou et al., Comparative Effectiveness Research and Evidence-Based Health
Policy: Experiencefrom Four Countries, 87 MILIBANK Q. 339, 362-63 (2009) (Of course,
the problem with this argument is its lack of obvious boundaries. In theory, for example,
looser FDA efficacy or safety standards would also increase investment in innovation, by
decreasing the risk that an expensive innovation would be excluded from the market. It is
far from obvious that we should discourage health care providers and patients from using the
most effective treatments simply in order to increase the incentives for medical innovations
because, as with safety and non-comparative effectiveness, there are countervailing policy
considerations. Furthermore, in countries whose governments support CER, there is no
empirical evidence suggesting that those efforts have hindered innovation.).
45. DOCTEUR AND BERENSON, supra note 32, at 9.
46. See Gail R. Wilensky, Developing A Center For Comparative Effectiveness

http://lawecommons.luc.edu/annals/vol21/iss2/4

10

Francis: Beyond Safe and Effective: The Role of the Federal Government in

2012]

Beyond "Safe and Effective"

339

the use of health care treatments,4 7 proponents have noted that CER has
potential to decrease health care costs while improving quality, for example,
by reducing waste in the health care system. 48
In recent decades, health care costs in the United States have far
outpaced overall inflation. 4 9 Although all developed countries have
struggled with cost control issues to some extent,50 American per capita
health care costs remain the highest in the world.5 1 As a consequence of the
high cost of health care in the United States, many Americans lack health
insurance.52 Moreover, the United States' aggregate health statistics are
mediocre relative to those of other developed countries, suggesting that
Americans do not get good value for their health care dollars.54 Thus, it is
Information, 25 HEALTH AFF. w572, w572-73 (2006).
47. See CBO, RESEARCH ON THE COMPARATIVE EFFECTIVENESS OF MEDICAL
TREATMENTS 12-15 (2007) [hereinafter 2007 CBO REPORT] (describing the results and

implications of the Dartmouth Atlas project); see generally Dartmouth Atlas of Health Care,
www.dartmouthatlast.org (last visited March 29, 2011).
48. See, e.g., Adam G. Elshaug & Alan M. Garber, How CER Could Pay for Itself Insightsfrom Vertebral Fracture Treatments, 364 NEw ENG. J. MED. 1390 (2011); but see
RAND
HEALTH
COMPARE,
ANALYSIS
OF
COMPARATIVE
EFFECTIVENESS,
http://www.randcompare.org/analysis-of-options/analysis-of-comparative-effectiveness
(last

visited March 30, 2011) (noting that "under some circumstances, using comparative
effectiveness research might reduce overall spending, but there is no clear evidence on the

direction or magnitude of the relationship"); see generally Ari Hoffman & Steven D.
Pearson, 'Marginal Medicine': Targeting Comparative Effectiveness Research To Reduce
Waste, 28 HEALTH AFF. w710 (2009) (describing four categories of "waste," or "marginal
medicine," for which CER might be helpful: "inadequate evidence of comparative net
benefit for any indication," "use beyond the boundaries of established not benefit," "higher
cost when established benefit is comparable to other options," and "relatively high cost for

incremental benefit compared to other options").
49. See generally The Economic Case for Health Reform: Hearing Before the H.R.
Comm. on the Budget, 111th Cong. (2009); BOB LYKE, CONGRESSIONAL RESEARCH SERVICE,
HEALTH CARE REFORM: AN INTRODUCTION, 4 (2009).
50. See Gerard F. Anderson et al., Health Spending In The United States And The Rest
Of The Industrialized World, 24 HEALTH AFF. 903, 906 (2005) (noting that "[i]n every
[OECD] country, growth in health spending outpaced inflation during the period 19922002," but even though this was a period of relatively stable health care spending in the
United States, "health spending as a percentage of [gross domestic product] increased by 1.6
percentage points. . . twice the OECD median"); see also "Members and Partners,"
http://www.oecd.org/document/25/ 0,3746,en_36734052_36761800 36999961 1_1 1 1,00.
html (last visited March 30, 2011) (OECD stands for the Organization for Economic
Cooperation and Development, which is a group composed of high-income countries.).
51. CHRIS L. PETERSON & RACHEL BURTON, REPORT FOR CONGRESS: U.S. HEALTH CARE
SPENDING: COMPARISON WITH OTHER OECD COUNTRIES (2007).
52. KAISER FAMILY FOUNDATION, THE UNINSURED AND THE DIFFERENCE HEALTH
INSURANCE MAKES (2010), available at http://www.kff.org/uninsured/upload/1420-12.pdf.
53.
See Peter A. Muennig and Sherry A. Glied, What Changes in Survival Rates Tell Us
About U.S. Health Care, 29 HEALTH AFF. 2105 (2010).

54. See Michael B. Rothberg et al., Little Evidence of CorrelationBetween Growth In
Health Care Spending And Reduced Mortality, 29 HEALTH AFT. 1523 (2010) (finding
"inconsistent value" associated with health care spending, with areas of good value "as well

Published by LAW eCommons, 2012

11

Annals of Health Law, Vol. 21 [2012], Iss. 2, Art. 4

340

Annals of Health Law

[Vol. 21

clear that there is room for both cost cutting and quality improvement in the
United States health care system, and to the extent that CER is capable of
contributing to these goals without causing problems that outweigh its
benefits, it could be an important (and relatively pain free)" component of
any plan to reform the health care system.
Underlying claims about the potential cost benefits of CER, however, is
the assumption that less expensive treatments will be found to be at least as
56
Although there is nothing
effective as more expensive treatments.
inherent to CER that requires this to be accurate, past experience suggests
that it may be a reasonable assumption. Even if CER does justify the use
of less expensive treatments, however, cost savings will only result if
consumers and providers actually alter their behaviors in favor of the lower
cost and more effective treatments, an outcome that is not supported by past
58
experience.
Some proponents of CER have also argued that better information about
the comparative effectiveness of different treatments will help, rather than
hinder, efforts to deliver increasingly personalized medicine to patients.
Withholding information from health care providers about the effectiveness
of possible treatments certainly does not make it easier to tailor a treatment
to a given patient's individual circumstances. 59 In addition to identifying
which treatments are more effective on average, researchers can use CER to
identify genetic or environmental subpopulations for which personalized
medicine is suitable or new applications for personalized medicine.o

as areas of apparent waste, where money might be better spent on research to find moreeffective therapies.").
55. Although CER is controversial, the fact that significant investments in CER
managed to pass Congress twice in two years suggests that this controversy pales into
comparison to any serious effort to enact more stringent methods of cost control.
56. DOCTEUR & BERENSON, supranote 32, at 8.
57. Id. (citing studies that found newer hypertension and anti-psychotic drugs to be no
more effective than older, less expensive drugs); see also Ezekiel J. Emanuel & Jeffrey B.
Liebman, Cut Medicare, Help Patients,N.Y. TIMEs, Aug. 22, 2011, at A25.
58. DOCTEUR & BERENSON, supra note 32.
59. Garber & Tunis, supra note 33, at 1926 ("[W]ith too few appropriately designed
studies, physicians, patients, and families often had little guidance about which patients were
most likely to benefit from a clinical strategy. Perhaps the most important goal of CER is to
broaden and deepen such information, providing tools for matching medical care much more
precisely to individual patients.").
60. Epstein & Teagarden, supra note 33, at 1784; C. Daniel Mullins et al., The Potential
Impact Of Comparative Effectiveness Research On The Health Of Minority Population, 29
HEALTH AFF. 2098, 2100 (2010) ("Ideally, comparative effectiveness research should lead to
the opposite of 'one size fits all' treatment by producing evidence and insights that are
applicable to subgroups of patients."); see Meier, supra note 38 ("'Ironically, the motivation
for comparative effectiveness is to see what works in practice,' [said Dr. Mark Helfand,
director of the Oregon Evidence-based Practice Center,] 'rather than overgeneralizing from a
few unrepresentative studies."').

http://lawecommons.luc.edu/annals/vol21/iss2/4

12

Francis: Beyond Safe and Effective: The Role of the Federal Government in

2012]1

Beyond "Safe and Effective"

341

Beyond personalizing treatments for individual patients, CER also has
potential to help providers recommend the best treatment for each unique
instance or variation of a given disease.61 Most importantly, however, CER
might be necessary to prove the relative effectiveness of personalized
medicine itself in order to encourage broader adoption among skeptical
health care providers.62
Lastly, even if CER is a blunt and imperfect tool, much criticism of CER
seem to imply that health care resources are not scarce, and the choice not
to adopt CER-based guidelines or insurance coverage rules is free. This is
clearly not the case. Despite the United States' remarkably high level of
health care spending, roughly fifty million people in the United States
remain uninsured.6 3 Holding this figure constant, and assuming the federal
government ultimately implements the ACA without significant changes
and the projection that the law will reduce the number of uninsured
Americans by 32 million is accurate, there will remain at least 23 million
uninsured residents in the United States. 64 While these people are likely to
have access to some health care, health insurance status has a significant
impact on access to health care; the uninsured often lack regular access to
health care services, and they are more likely to delay or forgo necessary
health care than the insured. 65 Thus, to the extent that the imperfection of
CER inhibits its use and results in value-less health expenditures, fewer
health care resources may be available to assist underserved populations
like the uninsured.
Even if the money saved by people with private insurance through use of
CER is not diverted toward underserved populations, there is another
subpopulation for which such a tradeoff is inevitable. Cash-strapped 6 6
61. Pauline Chen, Are Doctors Too Quick to Cut?: Variations and Exceptions, N.Y.
TIMES BLOG (Feb. 9, 2011, 19:49 EST), http://www.nytimes.com/roomfordebate/2011/02/
09/are-doctors-too-quick-to-cut/variations-and-exceptions-in-approaches-to-disease
(this
argument changed the mind of at least one group of stakeholders, cancer groups, during the
debate about CER in the ACA.); See John K. Iglehart, The PoliticalFight Over Comparative
Effectiveness Research, 29 HEALTH AFF. 1757, 1759 (2010).
62. Epstein & Teagarden, supra note 33, at 1785 ("There is ...
a paucity of
comparative effectiveness data showing the value of personalized medicine. We know from
the published literature that genetics can contribute to our understanding of drug response for
many commonly used medications . .. Yet routine use of these genetic tests is not supported
by many physician specialty organizations, nor is it covered by government or other insurers,
because data are lacking."); MCCLELLAN & BENNER, supra note 17, at 8.
63. KAISER FAMILY FOUNDATION, supra note 52.

64. See CBO, HEALTH CARE, http://www.cbo.gov/publications/collections/health.cfm
(last visited April 20, 2011) ("[The Congressional Budget Office] and the [Joint Committee
on Taxation] estimate that by 2019, the [ACA] will reduce the number of nonelderly people
who are uninsured by about 32 million, leaving about 23 million nonelderly residents
uninsured.").
65.

KAISER FAMILY FOUNDATION, supra note 52, at 2.

66.

See, e.g., Kevin Sack, For Governors, Medicaid Looks Ripe for Slashing, N.Y.
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safety net programs, like Medicaid, often must directly choose between
providing more generous benefits to current beneficiaries and expanding the
number of beneficiaries they can serve. For these programs, CER has the
potential to increase the amount of information available to policymakers
facing difficult tradeoffs, and could also help stretch available funding as
far as possible.
C. The Issue of Cost Effectiveness
As described above, one of the most contentious issues surrounding CER
is its potential use to "ration" access to costly care. But there is nothing
inherent to CER that requires the consideration of costs; it is entirely
possible to compare two treatments to determine whether one is more
effective for a given purpose without taking their relative costs into account.
Thus, the issue of whether CER should take costs into consideration is a
separate issue from whether it is beneficial to conduct, or use government
funds to subsidize, CER.
Proposals to incorporate cost considerations into CER typically advocate
for the use of cost-effectiveness analysis ("CEA"), in addition to
comparative-effectiveness analysis, to evaluate different treatments. While
CEA lacks a standard definition,67 generally speaking it is "a method
designed to assess the comparative impacts of expenditures on different
health interventions."68 A detailed analysis of the many complex issues
associated with CEA is beyond the scope of this Article. Suffice it to say
that CEA involves far more than technical number crunching, and
challenging technical and ethical questions are inherent to any effort to
quantify health. 6 9 Although researchers have developed a measure called
(Jan. 28, 2011), http://www.nytimes.com/2011/01/29/us/politics/29medicaid.html
?pagewanted=all (noting that the Governor of Arizona was seeking federal permission to
remove 280,000 adults from its Medicaid program, the Governor of California proposed
saving $1.7 billion through cuts including limiting beneficiaries' doctor visits and
prescriptions, and the Governor of Georgia proposed ending "Medicaid coverage of dental,
vision, and podiatry treatments for adults").
67. Peter D. Jacobson & Matthew L. Kanna, Cost-Effectiveness Analysis in the Courts:
Recent Trends and Future Prospects,26 J. HEALTH POL. POL'Y & L. 291, 293 (2001).
TIMES

68.

ALAN M. GARBER ET AL., COST-EFFECTIVENESS IN HEALTH AND MEDICINE 26-27

(Marthe R. Gold et al., eds. 1996); Alan M. Garber & Harold C. Sox, The Role Of Costs In
Comparative Effectiveness Research, 29 HEALTH AFF. 1805, 1808 (2010) ("The first step [in
CEA] is to define the lifetime health effects of each intervention. The next step is to
calculate the lifetime health care costs that would result from using each intervention. The
costs and health benefits of an intervention are then often used to calculate the so-called
incremental cost-effectiveness ratio . . . [which] is the difference in costs between the
intervention and an alternative, divided by the difference in their health outcomes or
effectiveness. This ratio is a measure of value: A low ratio indicates the expenditure has a
large positive effect on the patient's health, while a higher ratio indicates a smaller benefit, a
higher cost, or both.").
69. See, e.g., Paul Menzel et al., Toward a Broader View of Values in Cost-Effectiveness
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the "Quality Adjusted Life-Year" as an attempt to measure how a treatment
impacts the length and the quality of an individual's life,70 the tool remains
controversial.7 1
Opponents of incorporating cost into CER often express concerns about
the effects such research results might have on health care access, insurance
coverage, provider reimbursement, and the health care provider and patient
decision-making process.72 Even among supporters of CER and CEA,
however, there remains controversy over how closely to link the two forms
of research. Some observers argue in favor of fully integrating the two
forms of analysis. 73 They contend that cost is necessarily an important
element of health care provider and patient decision-making.74 Similarly,
Alan Garber and Harold Sox have argued that because the CER included in
the ACA will be partially funded by a tax on the health insurance industry,
the government should include cost information with CER results that
would at least be useful to insurance companies when making coverage
decisions, even if the government does not conduct CEA itself.76 Others
have argued that CEA should play a less prominent role in CER. The
Analysis of Health, 29 HASTINGS CENTER REP. 7 (1999) (advocating for better incorporation
of social values into CEA); Peter J. Neumann & Magnus Johannesson, From Principle To
Public Policy: Using Cost-Effectiveness Analysis, 13 HEALTH AFF. 206, 207-209 (1994)
(describing challenges associated with CEA, including the incorporation of patient
preferences). For example, people may value the costs of a treatment's adverse side effects
or the benefits of being relieved a specific condition differently. See Garber & Sox, supra
note 68, at 1808.
70. Garber & Sox, supra note 68, at 1808.
71. See infra Section I1(b)(3).
72. See, e.g., FEDERAL COORDINATING COUNCIL FOR COMPARATIVE EFFECTIVENESS
RESEARCH, REPORT TO THE PRESIDENT AND THE CONGRESS, supra note 11, at 57.
73. See, e.g., American College of Physicians, Information on Cost-Effectiveness: An
EssentialProduct of a National ComparativeEffectiveness Program, 148 ANNALS INTERNAL
MED. 956 (2008) (arguing for an independent federally funded entity that would develop
comparative-effectiveness and cost-effectiveness information, but suggesting that "cost
should never be used as the sole criterion for evaluating a clinical intervention"); Katherine
T. Adams, Rethinking ComparativeEffectiveness Research, 6 BIOTECHNOLOGY HEALTHCARE
35, 36 (2009) (quoting Dr. Donald Berwick, who later became the Center for Medicare &
Medicaid Services Administrator, "you could make [cost considerations] advisory, or you
could make it mandatory, or you could make it a policy rule. But to remain ignorant of the
cost implications of a drug that is marginally better than what is already out there is simply
bad policy.").
74. Garber & Sox, supra note 68, at 1809.
75. See infra note 288 and accompanying text.
76. Garber & Sox, supra note 68, at 1809-10; Alan M Garber, A Menu without Prices,
148 ANNALS INTERNAL MED. 964 (2008) ( analogizing the health care system to a restaurant
where the menu contains no prices, Garber notes that in such a circumstances, "we should
not be surprised by the size of the bill."); it is important to distinguish, however, concerns
about allowing any payer, including the federal government, to conduct CEA, and concerns
about having the same organization conduct the two forms of analysis for fear that CEA
would taint the effectiveness research. See 2007 CBO REPORT, supra note 47, at 26.
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American Heart Association has taken the position that CER "may include
estimates of cost and cost-effectiveness . .. but should focus on enhancing
value for patients rather than minimizing costs." 77 Even more firmly, health
economist Dr. Gail Wilensky has argued that CEA should be entirely
separate from any government effort to conduct CER, and that payers
should be the group that conducts (and pays for) CEA.
D. Rationalesfor Government Involvement in CER
Even if the balance of potential harms and benefits favors the pursuit of
CER, it does not necessarily follow that any level of government, and much
less the federal government, should be involved in CER. In fact, many
critics of recent CER initiatives have argued that while CER is generally
beneficial, it is both unnecessary and dangerous for the government to
conduct or rely on CER when making important policy decisions.7 9
Furthermore, the possibility of non-governmental actors conducting CER is
not just a theory, but a reality. Some health insurance and hospitals have
long played a role in generating and analyzing CER,s0 and pharmaceutical
companies have also begun to test their own products against others on the
market.81
77. Raymond J. Gibbons et al., The American Heart Association's Principles for
ComparativeEffectiveness Research, J. AM. HEART Ass'N 2955, 2955 (2009).
78. Gail Wilensky, Cost-Effectiveness Information: Yes, It's Important, but Keep It
Separate,Please!, 148 ANNALS INTERNAL MED. 967 (2008).

79. Michael F. Cannon, A Better Way to Generate and Use Comparative-Effectiveness
Research, POLICY ANALYSIS, Feb. 6, 2009, availableat http://www.cato.org/pubs/pas/pa632
.pdf; Helen Evans, Comparative Effectiveness in Health Care Reform: Lessons From
Abroad,

BACKGROUNDER,

Feb.

4,

2009,

at

2,

available

at

http://www.heritage.org/research/reports/2009/02/comparative-effectiveness-in-health-carereform-lessons-from-abroad; see Scott Gottlieb, Congress Wants to Restrict Drug Access,
WALL ST. J., Jan. 20, 2009, at A14; See Kavita Patel, Health Reform's Tortuous Route to the
Patient-CenteredOutcomes Research Institute, 29 HEALTH AFF. 1777, 1778 (2009) (even
among supporters of the ACA and its creation of a government agency to support CER, at
least two members of Congress initially favored a public-private entity, which they felt could
provide "a more efficient and transparent mechanism for the development and dissemination
of evidence-based medicine."); Cf Ronen Avraham, A Market Solution for Malpractice,
N.Y. TIMES, March 28, 2011, at A31 (arguing for medical malpractice reform whereby
health care providers who complied with best practice guidelines created by private sector
entities would be immune from liability).
80. Wilensky, supra note 46, at w574.
81. See, e.g., Tracy Staton, AZ Plots Push Into Comparative Effectiveness, FIERCE
PHARMA (Feb. 3, 2011, 11:25 AM), http://www.fiercepharma.com/story/az-plots-pushcomparative-effectiveness/2011-02-03
(describing
the plans of AstraZeneca, a
pharmaceutical company, to conduct CER on its own products); Shirley S. Wang,
Comparing Drugs Is 'Real World' Demand, New PhRMA Head Says, WALL ST. J. HEALTH
BLOG (Apr. 6, 2009, 8:53 AM), http://blogs.wsj.com/health/2009/04/06/comparing-drugs-isreal-world-demand-new-phrma headsays/?KEYWORDS=comparative+effectiveness+
research.

http://lawecommons.luc.edu/annals/vol21/iss2/4

16

Francis: Beyond Safe and Effective: The Role of the Federal Government in

Beyond "Safe and Effective"

2012]

345

The primary economic rationale for government involvement in CER is
that CER constitutes a "public good." A public good is both "nonexclusive" and "non-rivalrous," meaning that it is impractical to exclude
non-payers, but additional users do not inhibit the ability of previous users
to enjoy the good, respectively.82 Information about the comparative
effectiveness of different treatments fits within this model.83 Although it
would be possible to restrict access to the information, such restriction
would seem to defeat the purpose of generating the information in the first
place, and widespread use of the results of CER would not seem to harm
those who originally paid for the research. 84 Private actors tend to underproduce public goods, which arguably justifies government intervention to
increase production to efficient levels.Y Some observers disagree that the
federal government must intervene in the case of public goods, because
private markets will produce them under some circumstances.86 In the case
of CER, however, the public good problem may also lead private actors to
produce information narrowly tailored to their interests, resulting in
fragmented and duplicative research.
Even if private markets are incapable of producing efficient levels of
CER, some observers feel strongly that countervailing interests weigh
against government involvement. Government intervention can be costly in
terms of tax dollars, government decisions are subject to influence by
political and rent-seeking behavior, and there is no guarantee that the
government will produce the right type or optimal level of information. 8
At least one group has also argued that government participation in CER
has potential to "crowd out" private investment, because private
organizations that would have otherwise paid for CER themselves would
seek government funding to support the research. 8 9 Nonetheless, given that
82. Gail R. Wilensky, The Policies and Politics of Creating a Comparative Clinical
Effectiveness Research Center, 28 HEALTH AFF. w719, w721 (2009).
83. See 2007 CBO REPORT, supra note 47, at 8.
84. Wilensky, supra note 82, at w721 - w722.
85.

MEDICARE PAYMENT ADVISORY BOARD, REPORT TO THE CONGRESS: REFORMING THE

11l (2008) [hereinafter MEDPAC 2008]; Wilensky, supra note 46, at
w583.
86. See, e.g., Cannon, supra note 79, at 3-4 (noting that "[m]arkets increase the quantity
of nonexcludable goods ([for example] lobbying, research, charity) beyond the amount that
people are willing to purchase directly, by bundling them with excludable goods ([for
example] insurance, advertising, reputation, recreation). . . . Markets create incentives for
private actors to overcome the challenges posed by public goods. Innovators who develop
ways to solve the free-rider problem can capture the money that others leave on the table.").
87. Wilensky, supra note 82, at w722.; see also Fox, supra note 36, at 37-39 ( past
scandals involving research data produced by private health industry actors may contribute
to public distrust of privately sponsored research).
88. See Cannon, supra note 79, at 5.
89. Id. at 8-9.
DELIVERY SYSTEM
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private producers of CER have not generated enough information to fill the
vast knowledge gaps that proponents of CER point to when advocating for
more research, 90 it is at least reasonable to argue that the government could
play a beneficial role in funding, conducting, or encouraging private entities
to engage in more CER.
II. MODELS FOR GOVERNMENTAL PARTICIPATION IN CER

Before addressing the models of CER that the United States government
has adopted so far, it makes sense to survey a sample of the broad array of
options generally available to governments seeking to engage in CER.
These options demonstrate the trade-offs inherent to any effort to support
CER through the federal government, such as between independence,
credibility, and political accountability. 91 They also provide information
about the context and policy implications of the government's choices,
which can inform predictions about the future of the government's CER
efforts.
A. Domestic Possibilities
In its 2008 Report to Congress, the Medicare Payment Advisory Board
("MedPAC") 92 surveyed the CER proposals of eight observers. 93 Their
proposals included a separate CER agency within HHS, a public-private
partnership or a "quasi-governmental entity," a new organization within
AHRQ, or a "nonprofit independent institution."94 Beyond demonstrating
90. For example, a 2010 study found that only approximately one-third of studies on
medications published in "high-impact" general medical journals between June 2008 and
September 2009 qualified as CER.
Michael Hochman & Danny McCormick,
Characteristicsof PublishedComparative Effectiveness Studies of Medications, 303 JAMA
951 (2010). See also, e.g., MEDICARE PAYMENT ADVISORY COMMISSION, REPORT TO THE
CONGRESS: PROMOTING GREATER EFFICIENCY IN MEDICARE 29 (2007) [hereinafter MEDPAC
2007]) ("There is not enough credible, empirically based information for health care
providers and patients to make informed decisions about alternative services for diagnosing
and treatment most common clinical conditions. Many new services disseminate quickly
into routine medical care with little or no basis for knowing whether they outperform
existing treatments, and to what extent."). In addition, MedPAC has noted concerns that
some industry-sponsored CER studies have been insufficiently objective and transparent. Id.
at 40-41. The failure of the private sector to produce sufficient CER may be due in part to
the reluctance of major payers in the health care industry, and namely, Medicare, to demand
and use such information. Peter Orszag, Congressional Budget Office Testimony before the
Subcommittee on Health, Committee on Ways and Means, U.S. House of Representatives, 6
(June 12, 2007), available at http://www.cbo.gov/doc.cfm?index=8209&type=0.
91. See 2007 CBO REPORT, supra note 47, at 16-17.
92. About MedPAC, MEDPAC, http://www.medpac.gov/about.cfm (last visited Feb. 10,
2011) (MedPAC is "an independent Congressional Agency.. . [that advises] the U.S.
Congress on issues affecting the Medicare program.").
93. MEDPAC 2008, supra note 85, at 112.
94. Id.
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that there is a fairly broad range of ways in which the federal government
could increase support for CER, this array of options demonstrates that in
the years leading up to the passage of ARRA, it was far from obvious how
the government could best encourage CER. MedPAC itself argued in favor
of a public-private entity, with an independent board that would determine
and oversee the organization's research agenda, which would fund CER
studies. 95 The entity would sponsor and conduct research, serve as a
"clearinghouse" for published CER literature, and help coordinate existing
entities that also participate in CER. 96 MedPAC also emphasized the
importance of strict conflict-of-interest requirements for the entity, as well
as other ethics rules. 9 7
Another potential opportunity to conduct CER rests within the federal
Food and Drug Administration. Because of the role the FDA already plays
in compiling some data on drug, and to a lesser extent, device,98 safety and
efficacy (usually relative to a placebo), 99 the FDA would seem like a natural
home for CER.'00 One author went so far as to argue that the current
approval process harms patients, who may receive new treatments that are
more effective than a placebo, but less safe and effective than existing
treatments.' 0
Indeed, the FDA is already experimenting with the development of a
database of aggregated health information that could be used for a broad
range of research queries.1 0 2 So far, the FDA has mainly used this system
95. See MEDPAC 2008, supra note 85, at 111; see also MEDPAC 2007, supra note 90, at
41-49.
96. MEDPAC 2008, supra note 85, at 113-16.
97. Id. at 119-20.
98. Medical devices are subject to a different regulatory regime than drugs. Briefly, the
FDA divides devices into three classes based on safety risk, with the lowest class exempt
from FDA notification and approval requirements, the middle class subject to a "substantial
equivalence" standard with regard to a product already on the market, and the highest class
(including devices for which there is no existing substantially equivalent product) subject to
premarket approval that includes safety and efficacy analysis. See generally, Overview of
Device Regulation, U.S. FOOD AND DRUG ADMINISTRATION, http://www.fda.gov/Medical
Devices/DeviceRegulationandGuidance/Overview/default.htm#510k (last visited Mar. 30,
2011).
99. See MEDPAC 2007, supra note 90, at 33. In certain circumstances, such as when it
would be clearly unethical not to provide an unapproved drug to study participants, the FDA
may require proof of superiority to an existing alternative rather than a placebo. Randall S.
Stafford et al., New, but Not Improved? Incorporating Comparative Effectiveness
Information into FDA Labeling, 361 NEw ENG. J.MED. 230, 231(2009).
100. MEDPAC 2007, supra note 90, at 33 (notably, the FDA does not regulate surgical
and diagnostic procedures, which limits the impact and scope of any CER that the FDA
could undertake without significantly expanding its regulatory reach).
101. Alec B. O'Connor, Building Comparative Efficacy and Tolerability Into the FDA
Approval Process,303 JAMA 979 (2010).
102. Rachel E. Behrman et al., Developing the Sentinel System - A National Resource
for Evidence Development, 364 NEw ENG. J. MED. 498 (2011). While the Sentinel system is
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to react to safety problems, although it has potential for broader use that
includes CER.10 3 In order to conduct or facilitate CER, however, Congress
would need to expand the FDA's authority to change the type of
information it requires from drug and device manufacturers to include data
on comparisons to relevant alternative treatments. 10 4 Furthermore, to ensure
high quality CER, as opposed to studies designed to improve the odds of
FDA approval, the FDA would likely need to exercise some supervision
over the quality of submitted CER studies as well.105 The FDA could also
require the inclusion of comparative effectiveness information on drug
labels.106
Some observers have argued, however, that incorporation of CER into
the FDA's approval process would disrupt the FDA's "economic role as a
market regulator" that facilitates competition in the market for medical
treatments by approving all safe and effective drugs and devices for a given
condition.' 07 In addition, by using CER to serve as a gate keeping function,
the FDA might inadvertently bar treatments that would have otherwise
developed a comparative advantage over time, for example, if new
information were to become available about a drug's comparative
effectiveness or safety within a certain subpopulation.'os
Similarly, the government could use its authority under the Medicare and
Medicaid programs to require that treatment manufacturers submit CER
information in order to be covered under those programs. 109 As of June
2007, for example, CMS had begun to compile evidence about services not
covered in the past, and on occasion had also collaborated with other
federal agencies, such as AHRQ, to sponsor "head-to-head" trials and
technological assessments.110 Past efforts to incorporate CER into CMS

designed to help monitor product safety, however, its value is limited by the system's failure
to consider issues related to cost and scientific evidence. See Alexander & Stafford, supra
note 23, at 2490.
103. See Lynn M. Etheredge, CreatingA High-PerformanceSystem For Comparative
Effectiveness Research, 29 HEALTH AFF. 1761, 1762 (2010) (advocating for expansion of the
Sentinel Initiative to "systematically collect data on therapies' effectiveness, starting when a
new therapy first enters clinical practice.").
104. Wilensky, supra note 46, at w574; MEDPAC 2007, supra note 90, at 33 (noting
that, in addition to the fact that the agency's regulatory scope is limited and it usually looks
at studies comparing a product to a placebo, even for products required to submit clinical
trial results to the FDA, the typical study design is often not conducive to generating useful
information for CER. The FDA's limited authority with regard to post-market surveillance
of an approved product is another barrier to the agency's ability to participate in CER.).
105. O'Connor, supra note 101, at 979-80.
106. Stafford, supranote 99, at 1230.
107. Garrison Jr. et al., supra note 15, at 1815.
108. Id.
109. Wilensky, supra note 82, at w722.
110. MEDPAC 2007, supra note 90, at 34; 2007 CBO REPORT, supra note 47, at 11.
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coverage determinations have met political opposition, however, including
direct prohibitions from Congress."' Given this history and the controversy
surrounding the use of CER findings in health insurance coverage
determinations, it is clear that increased political support, at the least, would
be necessary for CMS to be a viable route toward the generation of more

CER studies."12
Alternatively, in 2006 Dr. Gail Wilensky proposed a center, either
funded publicly or through user-fees," 3 for CER that would "fund
prospective trials on key questions for which comparative effectiveness
evidence was found missing, in addition to funding systematic reviews of
existing research.""14 The center would focus on the generation of new
information, and would be located in such a way as to minimize conflict of
interest and stakeholder pressure, while maintaining a reputation for
producing "objective and credible" data. 5 Wilensky called for improved
coordination of health services research within the federal government,
perhaps by placing the CER center within the Agency for Healthcare
Research and Quality ("AHRQ") or elsewhere in the Department of Health
and Human Services ("HHS"), with CER on a particular treatment triggered
by FDA approval.1 6 As a substitute to a federal agency, Wilensky also
suggested that the center could exist either as a "quasi-governmental
entity," or within the private sector as a not-for-profit organization. She
noted, however, that the latter option lacked support as a realistic
possibility, either in the government or the private sector, as of 2006."'
In 2008, Senator Max Baucus (D-MT), proposed the creation of a similar
entity, the Health Care Comparative Effectiveness Research Institute, which
would have been a nonprofit corporation with the purpose of "advancing
the quality and thoroughness of evidence concerning the manner in which
diseases, disorders, and other health conditions can effectively and
appropriately be prevented, diagnosed, treated, and managed clinically
through research and evidence synthesis, and the dissemination of research
findings."" 8 The bill died in committee."'
In 2005, AcademyHealth, a non-profit organization focused on health
111. MEDPAC 2008, supra note 85, at 129; see also JACOBSON, supra note 14, at 29.
112. See MEDPAC 2008, supra note 85, at 130 (noting that additional statutory authority
for CMS would probably be necessary for the agency to effectively use CER findings).
113. Wilensky, supra note 46, at w583.
114. Id. at w577.
115. Id.
116. Id., at w578.
117. Id., at w580 - w582.
118. Comparative Effectiveness Research Act of 2008, S. 3408, 110th Cong. (2008).
119. For a list providing a sample of some other bills proposed in the 110th Congress to
support CER, as well as such bills proposed in the 109th Congress, see JACOBSON, supra
note 14, at 41-50.
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services research,12 0 also released a proposal for a center for CER within a
larger health services research agency in the federal government, with
AHRQ remaining the lead health services research agency. 12 1 The
organization then discussed four options to accomplish this goal, 122 but did
not endorse a particular option.123 Due to the contentious nature of some
CER, in which there may be "winners and losers" within the health care
industry,12 4 the report noted that its options would provide varying degrees
of political insulation for the research. AcademyHealth also identified five
"principles" that should govern Congress' decision about the placement of a
CER entity, including separation of scientific assessment from funding and
coverage issues, congressional oversight, stakeholder participation,
transparency, and funding for a broad range of research topics.12 5 Although
Congress did not ultimately adopt AcademyHealth's model CER entity in
its reauthorization of AHRQ, the organization's recommendations provide
useful analysis about some of the considerations that accompany the
balance between government accountability and autonomy from political
influences.
B. InternationalModels
Beyond the models, discussed above, that are designed around existing
institutions within, or characteristics of, the United States government, it is
also useful to briefly consider the models that other countries have used to
generate, support and use CER.12 6 The unique characteristics of the United
120. See About Us, ACADEMYHEALTH, http://www.academyhealth.org/About/content
.cfm?ItemNumber-2070(last visited Mar. 30, 2011).
121.
See generally ACADEMYHEALTH, PLACEMENT, COORDINATION, AND FUNDING OF
HEALTH SERVICES RESEARCH WITHIN THE FEDERAL GOVERNMENT, ACADEMYHEALTH,

(2005), availableat www.academy
health.org/files/publications/placementreport.pdf (noting that allowing AHRQ to remain the
lead agency for health services research "on par with the other HHS agencies" will ensure
visibility for the work and also encourageeffective interaction with other HHS agencies and
Congress);Id. at 3.
122. (1) AHRQ would sponsor and conduct the CER, but would be overseen by an
"external board and panel of experts;" (2) in addition to the first option, AHRQ would
establish an independent Federally Funded Research and Development Center ("FFDRC");
(3) a new, quasi-governmental entity would fund and conduct CER outside of AHRQ; and
(4) AHRQ would be converted to a quasi-governmental agency that would conduct CER as
well as carry out its existing functions. Id. at 11. An FFDRC is a federally funded entity
that operates as a private, not-for-profit organization; some FFDRCs are located within other
organizations. Id. at 15.
123. Id.at 10-11.
124. Id. at 9-10.
125.

ACADEMYHEALTH, supra note 121, at 12.

126. Notably, however, CER is an American term. Other countries refer to such
research as "health technology assessment" or "evidence-informed policymaking." Kalipso
Chalkidou et al., supra note 44, at 339.
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States health care system suggest that widespread integration of CER into
the health delivery system is likely to be more challenging in the United
States than in other developed countries.127 Nonetheless, one set of authors
has noted that CER in other countries tends to be a "demand-driven
activity," in the sense that it serves to meet "the needs of public and private
payers, patients, clinical professionals, and policymakers."l 2 8 Given that
those needs are likely to be, at the least, similar in the United States as in
other countries that have developed frameworks for supporting CER, the
experiences of those countries may provide some helpful lessons for the
road ahead in the United States.12 9
The model most frequently cited by critics of governmental CER efforts
in the United States is NICE in the United Kingdom. The United Kingdom
has a highly centralized 30 health system, the NHS, which provides care to
all residents with no point-of-service charge to consumers.131 Although the
NHS has been the subject of much criticism by opponents of health reform
in the United States, and domestic political pressure has led to some
reforms in the system,' 32 the NHS remains a very popular institution in the
United Kingdom.' 3 3 Within the NHS, NICE analyzes data about medical
technologies that are unusually significant in terms of cost, health
outcomes, or controversy.13 4 A group of academic experts analyzes CER
data, and then a group within NICE, the Technological Appraisal
Committee ("TAC"), which is made up of a variety of stakeholders, reviews
127. For example, because the United States has a "multipayer" system, any
organization or institution involved in CER must have strong legitimacy, through the
production of "objective and unbiased data," to support widespread adoption. Wilensky,
supra note 46, at w576.
128. Chalkidou et al., supra note 44, at 344.
129. For a general comparison of government-sponsored CER in the United Kingdom,
France, Germany and Australia, see id. at 345.
130. Note, however, that "NHS" is divided into four somewhat independent systems,
one for each of England, Northern Ireland, Scotland, and Wales. I refer to the NHS as
centralized in the sense that it is entirely taxpayer funded, the system's policies and budget
are largely set on a national level, and hospitals and physicians both contract directly with
the government for all of the services they provide. For a more nuanced description of the
NHS, see generally THE COMMONWEALTH FUND, THE ENGLISH HEATH CARE SYSTEM, 2009,
(2009),
available at http://www.commonwealthfund.org/Topics/Intemational-HealthPolicy/Countries/-/media/Files/Publications/Other/2010/Jun/International%20Profiles/1417
SquiresIntl ProfilesEngland.pdf.
131. See generally InternationalHealth Systems - UK, KAISEREDU.ORG, http://www
.kaiseredu.org/Issue-Modules/Intemational-Health-Systems/UK.aspx (last visited Mar. 30,
2011).
132. See The Final Frontier, THE EcoNoMisT, Jan. 13, 2011, at 59-60, available at
http://www.economist.com/node/1 7909835.
133. See Posting of Robert Mackey, to The Lede Blog (N.Y. Times), British Leaders
Defend Their Health Service, THE LEDE BLOG (Aug. 14, 2009, 12:38 EST),
http://thelede.blogs.nytimes.com/2009/08/14/british-leaders-defend-their-health-service/.
134. Wilensky, supra note 46, at w575.
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the evaluation and makes a recommendation. The recommendations of
TAC can be appealed, and the NHS may choose whether to adopt NICE's
ultimate recommendations, except to the extent that NICE recommends
coverage of a particular drug.' 3
As part of its original mission, NICE
explicitly conducts cost-effectiveness analysis for the treatments it studies.
136 NICE also conducts "budget impact analysis" as part of its evaluation,
but the latter does not factor into the entity's decisions.13 7
In addition to the United Kingdom, the governments of Australia,
Canada and Germany, among other countries and international
organizations,138 have also developed mechanisms that support CER. Like
the United States, Australia has a national health system called Medicare,
which provides health insurance for citizens, and some residents, of
Australia.' 39 In order to be included in Australia's national drug formulary,
a drug must be recommended by the Pharmaceutical Benefits Advisory
Committee ("PBAC").140 The PBAC, however, does not publish the
rationales or data supporting its recommendations,141 and CER efforts are
limited to prescription medications.142 Like NICE, the PBAC considers
cost-effectiveness analysis, but the committee also considers budget impact
analysis as part of its recommendations. 143 In support of the committee's
efforts, a 2001 study found that the PBAC might play a role in the relatively
low prices of pharmaceutical products in Australia. 144
Canada also has universal health insurance coverage through a health
system called Medicare, which is administered jointly by the federal,
provincial and territorial governments.14 5 Since 2003, Canada has had a
135. Id. at w576.
136. Chalkidou, supra note 44, at 350.
137. Id.
138. The Cochrane Collaboration is an example of an international organization that
reviews health care treatments to support the use of evidence-based medicine. See The
Cochrane Collaboration, About Us, http://www.cochrane.org/about-us (last visited Mar. 29,
2011); see also 2007 CBO REPORT, supra note 47, at 7.
139. See generally THE COMMONWEALTH FUND, THE AUSTRALIAN HEALTH CARE
SYSTEM, 2009 (2009), availableat http://www.commonwealthfund.org/Topics/InternationalHealthPolicy/Countries/-/media/Files/Publications/Other/2010/Jun/International%20Profiles
/1417_Squires Intl ProfilesAustralia.pdf.
140. Wilensky, supra note 46, at w575.
141. Id.
142. Chalkidou, supra note 44, at 347.
143. Id. at 350.
144. See INTERNATIONAL PHARMACEUTICAL PRICE DIFFERENCES, AUSTRALIA
PRODUCTIVITY COMMISSION, (2001), availableat http://www.pc.gov.au/projects/study/pbs

prices/docs/finalreport.
145.

See generally, THE COMMONWEALTH FUND, THE CANADIAN HEALTH CARE SYSTEM,

2009 (2009), available at http://www.commonwealthfund.org/Topics/International-HealthPolicy/Countries/-/media/Files/Publications/Other/2010/Jun/Intemational%20Profiles/1417
Squires IntlProfilesCanada.pdf.
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Common Drug Review ("CDR") procedure for new drugs. An expert
advisory committee analyzes the assessments of reviewers (either within or
external to the CDR), and makes a non-binding coverage recommendation
to the provinces, territories, and the federal government, which the
manufacturer may appeal. Canada's drug plans, however, follow the
CDR's recommendations approximately 90% of the time. 14 6 The CDR does
not publish either the data or assessment used for its recommendation, but
does make its rationale public. 147 Beyond analyzing the comparative
effectiveness of new drugs relative to current standard treatments, the CDR
also considers the comparative cost effectiveness of the drugs it studies. 148
In Germany, which has universal health insurance through a combination
of public and private health insurance plans,14 9 a publicly funded private
foundation called the Institute for Quality and Efficiency ("IQWiG")
evaluates drugs, treatments and clinical practice guidelines for certain
diseases."o Coverage decisions for the public health insurance plans
("Statutory Health Insurance"), which cover approximately 85% of the
German population, 51 hinge on IQWiG's reports,15 2 but there remains an
arm's-length relationship between IQWiG and the committee that
ultimately decides how to transform IQWiG's recommendations into health
policy.' 53 IQWiG considers scientific evidence about a wide range of
medical treatments, and since 2007, the organization has also considered the
results of cost-benefit and budget impact analyses.154 The institute then
disseminates the findings of its research through a website targeted at health
care consumers. 155
Among countries whose governments sponsor CER, a number of trends
are evident. The entities have varying levels of independence from both the
central governments that support them and other financial stakeholders.1 56
Other trends include: emphasis on transparency in topic selection, research

146. Fiona M. Clement et al, Using Effectiveness and Cost-effectiveness to Make Drug
Coverage Decisions, 302 JAMA 1437, 1438 (2009).
147. Wilensky, supra note 46, at w576.
148. Clement, supra note 146.
149. See generally REINHARD BUSSE & STEPHANIE STOCK, THE GERMAN HEALTH CARE
SYSTEM (2009), available at http://www.commonwealthfund.org/Topics/InternationalHealthPolicy/Countries/-/media/Files/Publications/Other/2010/Jun/International%20Profiles
/1417 _Squires IntlProfilesGermany.pdf.
150. Wilensky, supra note 46, at w576.
151. BUSSE & STOCK, supra note 149.
152. Wilensky, supra note 46, at w576.
153. Chalkidou, supra note 44, at 352-353.
154. Id. at 347, 350.
155. INFORMED HEALTH ONLINE, http://www.informedhealthonline.org/index.en.html
(last visited Mar. 30, 2011).
156. Chalkidou, supra note 44, at 357.
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analysis and final decisions, concern about scientific standards, the
inclusion of mechanism for reconsideration of decisions adverse to
stakeholders, and timeliness standards that require technologies to be
studied when they are relatively new and diffusion into the market is not yet
complete. 5 7 In addition, the entities often started out without taking into
account comparative cost information, but evolved to consider some forms
of CEA."' The entities tend to conduct research by synthesizing existing
studies rather than conducting their own prospective trials of new
technology, although evidence development, in the form of supporting
studies of new technologies, is increasingly important. 1 59 Studies have
found, however, that some of these programs face persistent problems with
the strength and quality of the evidence that they analyze, although they
address these challenges differently.16 0 Lastly, proponents of CER tend not
to emphasize cost control or rationing, but instead focus on the potential for
CER to improve health care quality and reduce waste.16 '
III. SOURCES OF SUPPORT FOR CER To DATE

A. Private
In addition to public entities, a number of private companies and
organizations participate in generating and analyzing CER. 162 Historically,
a significant source of privately funded and conducted CER has been the
Technology Evaluation Center ("TEC"), a program run by the Blue
Cross/Blue Shield Association in partnership with Kaiser Permanente.163
The TEC conducts approximately 20-25 assessments each year of drugs,
devices, and medical procedures to evaluate "clinical effectiveness and
appropriateness." 64 Some of these assessments include comparativeeffectiveness or cost-effectiveness studies.165 Despite the fact that the TEC
provides its assessments "solely for informational purposes," 66 the

157. Id.
158. Id. at 357-358.
159. Id. at 358-359.
160. Clement, supra note 146, at 1442.
161. Chalkidou, supra note 44, at 360.
162. See generally 2007 CBO REPORT, supra note 47, at 8.
163. Technology Evaluation Center, Technology Evaluation Center: Kaiser
Collaboration,BLUECROSS BLUESHIELD AssociATION, http://www.bcbs.com/blueresources/
tec/kaiser-collaboration.html (last visited March 30, 2011).
164. What is the Technology Evaluation Center?, BLUECROSS BLUESHIELD
ASSOCIATION, http://www.bcbs.com/blueresources/tec/what-is-tec.html (last visited March
30, 2011).
165. Id.
166. Id.
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organization does advise local Blue Cross/Blue Shield plans and other
entities that make insurance coverage decisions about the degree to which a
given technology is likely to improve health outcomes. 167 Other private
technology assessment companies, large health insurers, and managed care
organizations also conduct this type of research. 16 8
B. Public
1. Before 2009
Before the financial crisis of 2008 and the deep recession that followed
prompted Congress to pass ARRA,16 9the primary federal agency focusing
on CER was the Agency for Healthcare Research and Quality ("AHRQ").o70
CER, however, is not the agency's primary mission, which is generally "to
improve the quality, safety, efficiency, and effectiveness of health care for
all Americans." 17'
Originally, AHRQ was named the Agency for Health Care Policy and
Research ("AHCPR"). Congress created the AHCPR in 1989 in response
to concerns about waste in the health care system and the lack of scientific
support for many medical treatments, as well to serve as a replacement for
another now-extinct federal agency, the National Center for Health Services
Research and Health Care Technology Assessment.17 2 The AHCPR was
167.

TIMOTHY S. JOST, THE MEDICARE COVERAGE DETERMINATION PROCESS INTHE U.S.,

IN HEALTH CARE COVERAGE DETERMINATIONS: AN INT'L COMPARATIVE STUDY 208 (2005).

168.

Id. For an example of a consumer-oriented technology assessment program, see

Safe and Effective Drug Recommendations from Best Buy Drugs, CONSUMER REPORTS,

http://www.consumerreports.org/health/best-buy-drugs/index.htm (last visited March 30,
2011).
169. For a more detailed discussion about the federal government's history of
conducting and using comparative-effectiveness and cost-effectiveness information, see
generally JACOBSON, supra note 14, at 22-25, 29-33, 35.
170. The NIH is the primary funder of CER, but because the agency does not "tag" its
CER studies, they are not readily identifiable. FEDERAL COORDINATING COUNCIL FOR
COMPARATIVE EFFECTIVENESS RESEARCH, supra note 11, at 29. In a pilot identification
project, the Council found approximately 463 NIH-funded CER studies in the year 2008,
compared to 144 studies conducted by AHRQ during the fiscal years 2006-2009. Id. at 2829.
171. AHRQ At A Glance, AGENCY FOR HEALTHCARE RESEARCH AND QUALITY, http:
//www.ahrq.gov/about/ataglance.htm (last visited Mar. 30, 2011).
172. See Bradford H. Gray, The Legislative Battle Over Health Services Research, 11
HEALTH AFF. 38, 62 (1992) (describing the legislative history of the creation of the AHCPR,
and noting that its creation "was driven substantially by outcomes research and the hope that
such research might help to prevent unnecessary Medicare spending."). In analyzing the
legislative history of the creation of the AHCPR, Gray emphasizes that the agency serves as
a valuable case study regarding the federal government's difficulty in making health policy,
even in the face of a "rational response to a significant problem" and bipartisan support. Id.
at 64-65. The number of agencies that Congress has created and dissolved in relation to
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authorized to conduct research, demonstration projects, and trainings, as
well as to develop guidelines and disseminate research findings.1 3
Advocates for outcomes research, however, made a conscious decision to
separate the agency from the Health Care Financing Administration in order
to avoid highlighting the cost-containment implications of the research.17 4
Health services research generally, however, faced problems related to
the reality that, unlike other forms of research, it lacks a large constituency
of non-research advocates.' 75 Despite that the AHCPR had been created
during a Republican presidential administration and with the support of key
conservative members of Congress, the agency nearly lost its funding
during the battles over the federal budget in 1995-1996, when critics argued
that it was wasteful and ineffective.176 Particularly controversial was
Congress' decision in 1992 to direct the agency to consider costeffectiveness in its assessments. 177 The AHCPR's links with the failed
Clinton health reform effort, and pushback from surgeons in response to a
report that found insufficient evidence to support spinal fusion surgery for
low-back pain, also caused the agency political problems. 78
With the support of a number of professional organizations, advocacy
groups, and individual supporters, however, the agency survived, albeit
with a significantly reduced budget.17 9 The agency re-focused its efforts on
health care quality issues and dissemination and also shifted away from the
politically controversial practice of directly developing practice guidelines,
which were then created by non-governmental organizations through the
use of external evidence-based practice centers. 80 The agency's 1999
reauthorization legislation removed the word "policy" from its name,
thus transforming the agency into AHRQ. 18 2
Today, as in the years leading up to the passage of ARRA and the ACA,
AHRQ primarily engages in secondary CER, by conducting systematic
reviews and syntheses of existing research through its Effective Health Care
CER and similar research, starting in the 1970s and continuing through the present, may be a
symptom of the difficult political environment facing health policy decisions. See 2007
CBO REPORT, supra note 47, at 9.
173. Gray, supra note 172, at 40.
174. Id. at 63.
175. Bradford H. Gray et al., AHCPR And The Changing Politic Of Health Services
Research, 22 HEALTH AFF. w3-283, 285 (2003).
176. Id. at 294-296.
177. JACOBSON, supra note 14, at 23.
178. Gray, supra note 175, at 296-98.
179. Id. at 299-301.
180. Id at 302-03.
181. Healthcare Research and Quality Act of 1999, § 901(a), P.L. 106-129 (1999)
(codified at 42 U.S.C. § 299 et seq.) (1999)).
182. Gray, supra note 175, at 303.
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Program. s3 To accomplish this task, AHRQ contracts with thirteen
"evidence-based centers," that carry out systematic reviews and technology
assessments as well as some cost-effectiveness analyses,18 4 about the
agency's fourteen priority conditions that are of particular significance to
the Medicare, Medicaid or Children's Health Insurance programs.1
AHRQ notifies manufacturers when it begins reviews of their products and
The agency then
solicits public comments and other stakeholder input.'
disseminates this information to health care providers and consumers
through a series of guides, in the form of documents, videos, and audio
files, some of which are also provided in Spanish."'
Other federal agencies also conduct or support CER. The NIH is the
agency within the federal government that funds the most CER through
grants, 188 but until recently it had not sought to identify which of its funded
studies qualify as CER.18 9 The United States Preventive Services Task
183. FEDERAL COORDINATING COUNCIL FOR COMPARATIVE EFFECTIVENESS RESEARCH,
supra note 11, at 31; Jean R. Slutsky & Carolyn M. Clancy, AHRQ's Effective Health Care
Program: Why ComparativeEffectiveness Matters, 24 AM. J. MED. QUALITY 67, 67 (2009)
(in an article written by the Director of AHRQ and the Director of the agency's Center for
Outcomes and Evidence, the authors argue that AHRQ's program is unique due to its
"relevance, timeliness, and transparency"). The Effective Health Care Program was created
by the Medicare Modernization Act of 2003, P. L. 108-173, 108th Cong., § 1013 (2003), to
study "the outcomes, comparative clinical effectiveness, and appropriateness of health care
items and services. .. and strategies for improving the efficiency and effectiveness of such
[Medicare, Medicaid and CHIP], including the ways in which such items and services are
organized, managed, and delivered under such programs." Id. § 1013(a)(1)(A)(i-ii).
184. MEDPAC 2007, supra note 90, at 37.
185. The fourteen conditions are: "arthritis and nontraumatic joint disorders; cancer;
cardiovascular disease, including stroke and hypertension; dementia, including Alzheimer's
disease; depression and other mental health disorders; developmental delays, attentiondeficit/hyperactivity disorder, and autism; diabetes mellitus; functional limitations and
disability; infectious diseases, including human immunodeficiency virus and AIDS; obesity,
peptic ulcer disease and dyspepsia; pregnancy, including preterm birth; pulmonary disease
and asthma; [and] substance abuse." Slutsky & Clansy, supra note 183, at 68. Medicare,
Medicaid and the Children's Health Insurance Program are governed by Titles XVIII, XIX,
and XXI, respectively, of the Social Security Act.
186. Id.
187. See, e.g.,Choosing Pain Medicine for Osteoarthritis,AGENCY FOR HEALTHCARE
RESEARCH AND QUALITY,

http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-

reviews-and-reports/?pageaction=displayproduct&productid=4
(last visited March 30,
2011); Medicamentos Antideprisivos: Guia Para Adultos con Depresion, AGENCY FOR
HEALTHCARE RESEARCH AND QUALITY, http://effectivehealthcare.ahrq.gov/index.cfn/search-

for-guides-reviews-and reports/?pageaction=displayproduct&productlD=153&retumpage=
(last visited March 30, 2011); Comparative Effectiveness of Management Strategies for
Gastrophageal Reflux Disease, AGENCY

FOR HEALTHCARE RESEARCH AND QUALITY,

http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-andreports/?pageaction=displayproduct&productid=42 (last visited March 30, 2011).
188. MEDPAC 2007, supra note 90, at 37.
189.

FEDERAL COORDINATING COUNCIL FOR COMPARATIVE EFFECTIVENESS RESEARCH,

supra note 11, at 28-29.
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Force, an independent panel of scientific experts that works in collaboration
with AHRQ, also assesses the effectiveness of a variety of preventive health
care services and issues recommendations that serve as the "gold standard"
for preventive health care services.1 90 During fiscal years 2006 through
2009, the Department of Defense ("DoD") also conducted approximately
twenty-five CER studies, and the Veterans Health Administration ("VHA")
conducted ninety-six. 19 1
The VHA's role in conducting CER relevant to its patient population,
and particularly "practical" CER, is notable. 192 In addition, the VHA
sometimes requires that the manufacturers of products it might buy submit
cost-effectiveness analyses, particularly with regard to drugs that appear to
be marginally more effective, but much more expensive than alternatives. 19 3
A prominent example of CER conducted with the support of the VHA was
the COURAGE trial (Clinical Outcomes Utilizing Revascularization and
Aggressive Drug Evaluation), whose results were published in the New
England Journal of Medicine in 2007.194 The study found no additional
benefits (in the form of long term death rates, nonfatal heart attacks or
hospitalization for acute coronary syndromes) to the use of coronary stents
or other scaffolding ("percutaneous coronary intervention" or "PCI")
among individuals with stable coronary artery disease, when used for initial
disease management purposes. 195 Although the study's results were
groundbreaking, many cardiologists resisted incorporating the findings into
everyday practice by failing to conduct tests to determine whether PCI is
appropriate for particular patients given the study's findings.196 While some
of the resistance likely derived from disagreement with characteristics of
the study, the financial incentives facing physicians and device
manufacturers also probably played a role, given the high price of stent
procedures and the fact that insurers mostly did not restrict coverage of the
procedures based on the outcome of the study.19 7 The VHA's experience
190.

About the USPSTF: Introduction, U.S.

PREVENTIVE SERVICES TASK FORCE,

http://www.uspreventiveservicestaskforce.org/intro.htm (last updated Dec. 2010);
U.S. Preventive Services Task Force, AGENCY FOR HEALTHCARE RESEARCH AND
http://www.ahrq.gov/clinic/uspstfix.htm (last visited Mar. 30, 2011).
191.

QUALITY,

FEDERAL COORDINATING COUNCIL FOR COMPARATIVE EFFECTIVENESS RESEARCH,

supra note 11, at 30.
192. Id.at3l.
193. MEDPAC 2007, supra note 90, at 37.
194. Willam E. Boden et al., Optimal Medical Therapy with or without PC] for Stable
CoronaryDisease, 356 NEW ENG. J. MED. 1503 (2007). The Congressional Budget Office
used this study as an example of CER disproving a widely held belief in its 2007 paper for
Congress on CER. 2007 CBO REPORT, supra note 47, at 4.
195. Boden, supra note 194, at 1514.
196. Keith J. Winstein, A Simple Health-Care Fix Fizzles Out, WALL ST. J., Feb. 11,
2010, at Al.
197. Id.
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thus demonstrates the complex nature, not only of disseminating CER
findings, but ensuring that health care providers accept and incorporate the
results into practice. 198 Yet, the VHA is unique because it has a dedicated
initiative'" and center200 that assist with the implementation of research
findings within the VA health care system and tackle these challenges headon.
In addition to the federally funded CER programs, states have also
engaged in activities to generate and use CER.20' The Drug Effectiveness
Review Project ("DERP") at the Oregon Health and Science University
conducts systematic comparative-effectiveness reviews for a self-managed
and collaborative group of eleven states, as well as the Canadian Agency
for Drugs and Technologies in Health.202 Although DERP provides
members with the findings of CER studies of drugs (which do not include
CEA or other cost considerations), members retain total freedom with
regard to how the information influences their policy decisions.203
Likewise, the state of Washington also has a health technology assessment
program ("HTAP"). 204 Unlike DERP, the HTAP explicitly considers
205
Nonetheless, the HTAP
whether a studied technology is cost effective.
has faced problems. For example, when the program sought to incorporate
198. Interestingly, the dissemination of CER regarding PCI as a treatment for acute heart
attacks was a success. See Aanand D. Naik & Laura A Petersen, The Neglected Purpose of
Comparative-EffectivenessResearch, 360 NEW ENG. J. MED. 1929, 1930 (2009).
199. Quality Enhancement Research Initiative (QUERI), U.S. DEP'T OF VETERANS
AFFAIRS, http://www.
queri.research.va.gov/ (last updated Nov. 4, 2011).
200. QUERI Centerfor Implementation Practice and Research Support, U.S. DEP'T OF
VETERANS AFFAIRS, http://www.queri.research.va.gov/ciprs.cfm (last updated Oct 22, 2009).
201. For charts comparing the types of CER conducted or supported by AHRQ, NIH,
the Department of Defense, and the VHA, see MEDPAC 2007, supra note 90, at 32.
202. See generally, Drug Effectiveness Review Project (DERP), OR. HEALTH & SCI.
UNIV., http://www.ohsu
.edu/xd/research/centers-institutes/evidence-based-policy-center/derp/index.cfn/ (last visited
Mar. 30, 2011); MEDPAC 2007, supra note 90, at 38, 40. For the current members of
DERP, see ParticipatingOrganizations,OR. HEALTH & SCI. UNIV., http://www.ohsu.edu/xd/
research/centers-institutes/evidence-based-policy-center/derp/participatingorganizations.cfm
(last visited March 30, 2011). For analysis of the challenges and successes of the project,
which began in 2003, see generally, Peter J. Neumann, Emerging Lessons from the Drug
Effectiveness Review Project, 25 HEALTH AFF. w262 (2006); see also Mark Gibson & John
Santa, The Drug Effectiveness Review Project: An Important Step Forward,25 HEALTH AFF.
w272 (2006) (rebutting criticisms of the project).
203. Neumann, supra note 202, at w263-64.
204. MEDPAC 2007, supra note 90, at 38; Health Technology Assessment Program
(HTA), WASH. STATE HEALTH CARE AUTH., http://www.hta.hca.wa.gov/ (last visited March
30, 2011).
205. About the Program,WASH. STATE HEALTH CARE AUTH., http://www.hta.hca.wa.
gov/about.html
(last visited March 30, 2011).
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the results of the VHA's COURAGE study into the state's health insurance
programs by conducting a review of the evidence supporting stents, it
encountered significant industry opposition.2 06 The external firm it hired to
conduct the review decided the study was not feasible after industry leaders
and physicians declined to cooperate.207 As a consequence, HTAP had to
conduct a narrower review that did not follow the COURAGE study.208
2. ARRA
In early 2009, Congress passed the American Recovery and
Reinvestment Act. Although the bill was, at least ostensibly, a necessary
emergency response to the financial crisis and economic recession that
began in December 2007,209 it was a controversial piece of legislation.2 10
One aspect of the statute that failed to garner much attention before its
passage, probably due to the law's fast legislative timeline and complexity,
was its significant investments in CER.
Two sections of ARRA address CER. The first, section 804, created the
Federal Coordinating Council for Comparative Effectiveness Research
("Coordinating Council"). 2 11 The statute described the purpose of the
Coordinating Council as fostering "optimum coordination of comparative
effectiveness and related health services research conducted or supported by
relevant Federal departments and agencies, with the goal of reducing
duplicative efforts and encouraging coordinated and complementary use of
resources."212 To meet this objective, the statute required the Coordinating
Council to have at most fifteen members that are all federal employees or
officers to be appointed by the President through the Secretary of HHS.213
Section 804 required the Council to submit annual reports to Congress and
the President about the federal government's CER efforts, but the law
explicitly stated that section 804 did not give the Council authority "to

206. Winstein, supra note 196.
207. Id. ("We don't want to end up being our own willing executioners," said ... the
senior director of health economics for . .. a stent maker" on a call with the firm.).
208. Id.
209. See Edmund L. Andrews, Officials Vow to Act Amid Signs ofLong Recession, N.Y.
TIMEs, Dec. 1, 2008, at Al.

210. See, e.g., Op-Ed., The Stimulus Tragedy, WALL ST. J., Feb. 7, 2009, at Al (arguing
the stimulus was too large); Leslie Eaton, Governors Agree on Woes But Disagree on
Stimulus, WALL ST. J., Feb. 23, 2009, at A3; Paul Krugman, Failure to Rise, N.Y. TIMES,
Feb. 12, 2009, at A31 (arguing the stimulus was too small).
211. Pub. L. No. 111-5, § 804, 123 Stat. 115, 187(2009).
212. Id § 804(b).
213. Id. § 804(d). ARRA also required that eight health-related federal agencies have
representatives on the board (AHRQ, CMS, National Institutes of Health, Office of the
National Coordinator for Health Information Technology, FDA, Veterans Health
Administration, and the Department of Defense).
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mandate coverage, reimbursement, or other policies for any public or
private payer." 2 14 The Coordinating Council, however, was a short-lived
endeavor. Section 6302 of the ACA terminated the Council as of the date
of its enactment, March 23, 2010, just over a year after the passage of
ARRA.
The second section of ARRA that addresses CER is in Title VIII of the
statute, which appropriates a total of $1.1 billion for the research. Of that
sum, Congress allocated $400 million to the National Institutes of Health
("NIH"), $400 million to the Secretary of HHS (to distribute at her
discretion), and $300 million to AHRQ.215 Congress required that the
money be spent on
efforts that: (1) conduct, support, or synthesize research that compares
the clinical outcomes, effectiveness, and appropriateness of items,
services, and procedures that are used to prevent, diagnose, or treat
diseases, disorders, and other health conditions; and (2) encourage the
development and use of clinical registries, clinical data networks, and
other forms of electronic health data that can be used to generate or
obtain outcomes data." 216
Section one follows the definition of CER used by Congress in the
Stimulus Act. . In conjunction with the funds, Congress required HHS to
contract with the IOM to issue a report on national priorities for CER.
Congress then instructed the Secretary of HHS to consider this report, as
well as recommendations by the Coordinating Council, when funding CER
projects and awarding grants. The statute also ordered that the funded
agencies provide reports to Congress, and that grantees allow for public
comment on their research, "to the extent feasible."
ARRA's provisions on CER generated significant after-the-fact criticism.
217 For the most part, critics argued that the provisions represented a covert
effort at government rationing of health care21 8 and an unjustified
214. Id. §§804(e), (g)(1).
215. See id.
216. Id.
217. However, some criticism of ARRA's CER provisions predated the passage of the
law. See, e.g., Scott Gottlieb, supra note 79, at A14.
218. See, e.g., George F. Will, Stimulus Math for the GOP, WASH. POST, Jan. 29, 2009,
at A19; Betsy McCaughey, GovernmentCare's Assault on Seniors, WALL ST. J., July 23,
2009, at Al5 ("The assault against seniors began with the stimulus package in February.
Slipped into the bill was substantial funding for comparative effectiveness research, which is
generally code for limiting care based on the patient's age."); Betsey McCaughey, Ruin Your
Health With The Obama Stimulus Plan, BLOOMBERG, Feb. 9, 2009 (suggesting that ARRA's
investments in CER, in combination with its investments in health information technology,
will result in the federal government monitoring "treatments to make sure your doctor is
doing what the federal government deems appropriate and cost effective."). McCaughey's
claim, similar to one made by the Heritage Foundation a few days earlier, was also picked up
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interference into the physician-patient relationship. 2191n the aftermath of
ARRA, at least one member of Congress went so far as to vote against the
appointment of Kathleen Sibelius as the Secretary of Health and Human
Services because of concerns related to CER. 220 On the surface, the strong
negative reaction of some Republicans to the inclusion of CER in ARRA
was somewhat surprising, both because the general idea of CER, if not the
details, is relatively uncontroversial and because a number of prominent
Republicans, including 2008 presidential candidate Senator John McCain,
had formerly supported the research. 221 Regardless, concerns over
ARRA's investment in CER were still simmering as Congress began in
earnest to debate comprehensive reform of the health care system in mid2009.
Although the retrospective significance of ARRA's investment in CER
changed dramatically with the passage of the ACA in the spring of 2010,
and any evidence on the impact of CER funded by ARRA on the health
system is years away, some results and lessons from the legislation are
available today. In response to ARRA's legislative mandate, the IOM
released its report to Congress and Secretary of HHS on June 30, 2009. 222
In its report, the IOM identified the 100 topics, based on stakeholder input,
which should take priority in CER research, divided into four quartiles to
indicate priority within the list as a whole. 223 The report also included
"recommendations for a robust national CER enterprise," in which the IOM
advocated for a number of policy reforms that would facilitate an on-going
prioritization, monitoring and evaluation process for federally-sponsored

by Rush Limbaugh. See NINA OWCHARENKO, THE STIMULUS BILL: WHY THE SENATE MUST
Fix
THE
HEALTH
CARE
PROVISIONS
(2009)
available
at
http://www.heritage.org/research/reports/2009/02/the-stimulus-bill-why-the-senate-must-fixthe-health-care-provisions; Rush Limbaugh, The March To Socialized Medicine Starts In
Obama's Porkulus Bill, RUSHLIMBAUGH (Feb. 9, 2009), http://www.rushlimbaugh.com
/home/daily/site_020909/content/01 125111 .guest.html.
219. See OWCHARENKO, supra note 218. In May 2010, a Federal District Court for the
Southern District of New York granted the government's motion to dismiss a suit that
argued, among other things, that the CER provisions of ARRA "lay[ed] the groundwork for
a permanent government rationing board" and that the Coordinating Council would
"prescribe what care, procedures or medications [plaintiffs] will receive in place of the
doctors chosen by the Plaintiffs and the Plaintiffs themselves." The Court noted that such
assertions were "completely unsupported by the statute." Heghmann v. Sibelius, 2010 U.S.
Dist. LEXIS 71965, at *1l (S.D.N.Y. 2010) (internal quotations omitted).
220. Jane Zhang, Sen. Kyl Explains His Vote Against Sibelius, WALL ST. J. (Apr. 21,
2009, 3:15pm ET), http://blogs.wsj.com/washwire/2009/04/21/9782/.
221. Iglehart, supra note 61, at 1758. AHRQ and its predecessor also had bipartisan
support, although conservative support for the agency partially broke down during the 1990s.
See supranotes 172-192 (describing the history of AHRQ).
222.

IOM NATIONAL PRIORITIES FOR CER, supra note 7, at 21.

223.

Id. at 3-12.
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CER, with a high degree of transparency and public involvement. 224 The
IOM also called for additional research into CER methods, improved data
collection methods, increased capacity in the CER workforce, and a
sustained effort to diffuse CER findings. 225
On the same day that the IOM published its report, the Federal
Coordinating Council for Comparative Effectiveness Research 226 released
its Report to the President and the Congress. 227 To gather information for
the report, the Council held a series of "listening sessions," in which a
variety of stakeholders had an opportunity to provide testimony and
comments on the subject of CER. 228 The comments generally focused on
research prioritization, infrastructure development (including "human and
scientific capital, organizational capacity, and data capacity"), research
methodology, care delivery, knowledge transfer, cost, health disparities, and
personalized medicine. 2 29 Notably, in its report, the Council focused on the
"patient centered" aspect of CER,230 which it suggested could help answer
the question of "which therapeutic choice works best for whom, when, and
in what circumstances" and help patients "take responsibility for their
care."231 In a preview of how advocates for CER would frame the issue in
the ACA, the report notes that CER can also be called "patient-centered
health research or patient-centered outcomes research to illustrate its focus
on patient needs."232 The Council recommended that the Secretary of HHS
spend ARRA's $400 billion in discretionary funds primarily on data
infrastructure and then on "dissemination and translation of CER findings,
priority populations, and priority types of interventions" secondarily. 233
224. Id. at 140-46.
225. Id. at 146-59.
226. For the Council's membership, see Federal CoordinatingCouncilfor Comparative
Effectiveness Research Membership, HHS.GOV, http://www.hhs.gov/recovery/programs/os/
cerbios.html (last visited Mar. 30, 2011). For summaries of the Council's pre-report
meetings, see FEDERAL COORDINATING COUNCIL FOR COMPARATIVE EFFECTIVENESS
RESEARCH, supra note 11, at 59-64.
227.

FEDERAL COORDINATING COUNCIL FOR COMPARATIVE EFFECTIVENESS RESEARCH,

supra note 11.
228. Summaries and transcripts from these listening sessions are available at
ComparativeEffectiveness Research Funding, HHS.Gov, http://www.hhs.gov/recovery
/programs/cer/index.html (last visited March 30, 2011).
229.

FEDERAL COORDINATING COUNCIL FOR COMPARATIVE EFFECTIVENESS RESEARCH,

supra note 11, at 53-59 (summarizing trends in the comments and testimony).
230. For the Council's definition of CER, see supra text accompanying note 11.
231.

FEDERAL COORDINATING COUNCIL FOR COMPARATIVE EFFECTIVENESS RESEARCH,

supra note 11, at 3.
232. Id. at 4. The Council identified several priority subpopulations, "including racial
and ethnic minorities, individuals with disabilities, children, persons with multiple chronic
conditions, and the elderly," based on underrepresentation in previous research, increased
disease burden, and health disparities. Id. at 18.
233. Id. at 44-48.
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Congress required the three federal agencies to award the funds provided
by September 30, 2010.234 By August 2010, the federal government had
allocated at least 82.8 percent of the $1.1 billion in CER funding included
in ARRA, although only half of that amount had already been awarded to
specific grantees.235 Of the amount allocated, roughly half was designated
for "evidence development and synthesis activities."236 Most of the rest
went toward building CER capacity- approximately 7% was aimed at
efforts to translate and disseminate evidence and a total of approximately
5% was or will be spent to set priorities and engage stakeholders.23 7
3. The ACA
Although ARRA's investment in CER arguably set the stage for
prominent inclusion of CER in Congress' effort to reform the health care
system,238 it did not provide a clear picture of what a permanent expansion
of federal CER efforts would look like. When Congress shifted its primary
focus toward health reform in the spring of 2009, it became apparent that
CER was one of the issues for which there was a difference of opinion
between members of the Senate and the House of Representatives, in
addition to the recently diverged positions on the issue held by members of
Congress from the two major political parties.239 One of the early major
bills debated in the Senate, the "Affordable Health Choices Act" (also
known as the "Senate HELP Committee bill" or the "Kennedy bill" due to
Senator Kennedy's role in forming the bill before his death later that year),
included a "Center for Health Outcomes Research and Evaluation" within
AHRQ. 240 Although the bill expressly provided that the Center's "reports
and recommendations [would] not be construed as mandates for payment,
coverage, or treatment," 241 the bill faced stiff opposition by Senate

234. Joshua S. Benner et al., An Evaluation Of Recent Federal Spending On
Comparative Effectiveness Research: Priorities, Gaps, And Next Steps, 29 HEALTH AFF.
1768, 1769 (2010).
235. Id.
236. Id. at 1770.
237. Id.
238. While ARRA may have been the first major legislative step toward increased
federal support for CER, as well as a catalyst for increased public scrutiny and political
controversy over the issue, it is important to note that support for the research in Congress
started with the Democratic take-over of Congress in 2007. See Kavita Patel, supra note 79,
at 1777-78 (providing details about legislative efforts to support CER between 2007 and
2009). Patel notes that CER was supported in the platforms of both Barack Obama and John
McCain during the 2008 election). Id. at 1778.
239. Id.
240. Affordable Health Choices Act, S. 1679, 111th Cong. § 219 (2009).
241. Id.
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republicans.242
The first major bill debated by the House was H.R. 3200, "America's
Affordable Health Choices Act of 2009.",243 The bill included CER
provisions244 similar to those Democrats sought (and failed) to include in
one of the House's versions of a reauthorization bill for the Children's
Health Insurance Program in 2007.245 Like the Senate HELP bill, the bill's
Center for Comparative Effectiveness Research would have been located
with AHRQ. 246 Although there was some dissent among the House
Democrats about whether a fully public agency was the best way to support
CER, they decided to commit to the model.24 7 Thus, the health reform bill
that ultimately passed through the House on November 7, 2009248 ("House
Bill") called for a center within AHRQ "to conduct, support, and synthesize
research . . .

with

respect

to

the

outcomes,

effectiveness,

and

appropriateness of health care services and procedures in order to identify
the manner in which diseases, disorders, and other health conditions can
most effectively and appropriately be prevented, diagnosed, treated, and
managed clinically." 24 9
In contrast, the bill passed by the Senate on December 24, 200920
included the Patient-Centered Outcomes Research Institute ("PCORI"). 251
Senate Republicans opposed the PCORI, much as they had opposed the
inclusion of CER in the HELP bill, and the United States Preventive
Services Task Force amplified their concerns through its release of revised
breast cancer screening guidelines while the bill was still pending. 25 2 yet,
242. Patel, supra note 238, at 1779 (noting that Sen. Mike Enzi (R-WY) suggested that
the bill created "a new bureaucracy to dictate which treatments you pay for," other
Republicans compared the center to NICE in the United Kingdom, and Republican senators
proposed more than twenty amendments to eliminate the center from the bill on the first day
of its markup in the HELP Committee).
243. H.R. 3200, 111th Cong. (2009).
244. H.R. 3200, 111th Cong. § 1401 (2009).
245. H.R. 3162, 110th Cong. § 904 (2007).
246. Id.
247. Patel, supra note 238, at 1779.
248. Carl Hulse & Robert Pear, Sweeping Health Care Plan Passes House, N.Y. TIMES,
Nov. 8, 2009, at Al.
249. H.R. 3962, 111th Cong. § 1401(a) (2009).
250. See Robert Pear, Senate Passes Health Care Overhaul on Party Line Vote, N.Y.
TIMES, Dec. 25, 2009, at Al.
251. H.R. 3590, 111th Cong. (2009).
252. See Patel, supra note 238, at 1780; Op-Ed., Liberals and mammography, WALL ST.
J., Nov. 24, 2009, at A22 ("The flap over breast cancer screening has provided a fascinating
insight into the political future of ObamaCare. Specifically, the political left supports such
medical rationing even as it disavows that any such thing is happening. . . . [T]he distinction
between cost effectiveness and clinical effectiveness will be moot if ObamaCare passes....
Americans will simply have to accept that the price of government-run health care in the
name of redistributive justice is that patients and their doctors must bow to the superior
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the PCORI remained largely intact through the passage of the ACA and its
amendment by the Reconciliation Act.
Section 6301 of the ACA creates the PCORI.253 The statute provides that

the purpose of the PCORI is:
. .. to assist patients, clinicians, purchasers, and policy-makers in

making informed health decisions by advancing the quality and relevance
of evidence concerning the matter in which diseases, disorders, and other
health conditions can effectively and appropriately be prevented,
diagnosed, treated, monitored, and managed through research and
evidence synthesis that considers variations in patient subpopulations,
and the dissemination of research findings with respect to the relative
health outcomes, clinical effectiveness, and appropriateness of...
medical treatments. 254
Toward this end, the law requires the PCORI to identify research
priorities and project agenda, as well as to carry out its agenda through
research.255 Methodologically, the statute is flexible; while the statute
provides for general methodological standards, the Institute may use a
variety of research designs, including randomized trials, observational
studies, systematic reviews, and any "other methodologies recommended
by the methodology committee" established by the law, if adopted by the
Board of the PCORI.256 In order to conduct research, the statute authorizes
the Institute to contract with other federal agencies as well as nongovernmental entities that conduct research, although the Institute must
give preference to contracts with the NIH or AHRQ.m To contract with
the PCORI, a research entity must abide by the agency's transparency,

wisdom of HHS task forces."). In part, Democrats were able to assuage concerns related to
the new guidelines by including a section in the ACA requiring group health insurance plans
to cover mammography for women according to the most current guidelines other than the
controversial guidelines of November 2009. ACA § 1001.
253. ACA § 6301 (b) (tobe codified in Title XI of the Social Security Act, at 42 U.S.C. §
1301 et seq. (sections (a) and (d)), and 42 U.S.C. § 1320e-1 (section (c)), section 937 of the
Public Health services Act, at 42 U.S.C. § 299 et seq. (section (b)), and section 9511 of the
Internal Revenue Code of 1986 (sections (e) and (f)).
254. Id. at § 6301(c).
255. Congress accompanied this delegation of authority with the requirement that the
PCORI consider a number of factors, including "disease incidence, prevalence, and
burden . . . (with emphasis on chronic conditions), gaps in evidence . .. practice variations

and health disparities .. . the potential for new evidence to improve patient health, wellbeing, and the quality of care." Id. The Institute must also consider the effects of a "health
care treatment, strategy, or health" condition on national expenditures. Id. With regard to
the "patient-centered" aspect of the Institute's mission, it must take into account "patient
needs, outcomes, and preference," as well as relevance to decision-makers. Id

256. Id.
257. Id.
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conflict of interest, methodological, privacy, and ethics requirements. 25 8
The entity must also allow its researchers to publish their findings in peerreviewed "or other" publications, as long as each researcher has signed a
data-use agreement with the PCORI and complies with the Institute's
general peer-review process for original research. 25 9 The statute also grants
researchers the flexibility to contract for the inclusion of payment of
research participants' insurance co-pays and co-insurance, when
necessary.260 Significantly, the PCORI will have access to data collected by
CMS through Medicare, Medicaid, and the Children's Health Insurance
Program ("CHIP"), in addition to any registries or databases that the
PCORI assists in developing.26 1 In using this data the Institute remains
Along with this
bound by existing confidentiality and privacy laws.
access, however, is the requirement that the PCORI must periodically
"review and update" its research.26 3
The PCORI has the general authority to appoint expert advisory panels to
help set research priorities and agenda, and it must create such panels to
advise the agency with regard to randomized clinical trials and rare diseases
(to the extent the Institute undertakes studies of rare diseases).264 The
Institute must also create a methodology committee "to develop and
improve the science and methods of comparative clinical effectiveness
research" by updating "scientifically-based" methodological standards on
"internal validity, generalizability, feasibility . .. timeliness of research ...
health outcomes measures, risk adjustment, and other relevant aspects of
research and assessment." 2 65 This Committee must consider input from
stakeholders, experts, decision makers, and the public in developing its
standards.
For oversight, the PCORI is subject to annual financial audits, as well as
less frequent audits of its "processes," "dissemination and training activities
and data networks," its "overall effectiveness," and the "adequacy and use"
of its funds.267 The PCORI must provide a public comment period before
the adoption of its list of research priorities. It must also hold public
forums, disclose research findings (including processes and methods),

258.
259.
260.
261.

Id.
Id.
Id.
Id. The PCORI's authority to assist in "building data for research" can be found in

ACA § 6301(b).
262. ACA § 6301(a) (to be codified at 42 U.S.C. § 1301).
263.
264.
265.

Id.
Id.
Id.

266.

Id.

267.

Id.
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provide notice of public comment periods and publish the comments
received during those periods, and also make public some of its
proceedings.268 In addition, the Institute is subject to conflict of interest
disclosure requirements and a prohibition on gifts or donations.269
Beyond encouraging the publication of original research findings in peerreviewed journals, Congress also mandated that the PCORI make all
research findings "available to clinicians, patients, and the general
public." 2 70 These findings must be available in a "manner that is
comprehensible and useful to patients and providers in making health care
decisions," and must also "fully convey findings" related to the research's
applicability to subpopulations and its interaction with different risk
factors.271 The Institute must also convey the limits of the research and
discuss what further research may be necessary.27 2 Notably, the PCORI
may not include with its research findings "practice guidelines, coverage
recommendations, payment, or policy recommendations."2 73
To further encourage the diffusion of the results of the PCORI's
federally funded CER, Congress also charged the Office of Communication
and Knowledge Transfer ("OCKT") within AHRQ and the NIH with broad
dissemination of the Institute's research results and other federally
sponsored CER.m The OCKT, specifically, must "create informational
tools that organize and disseminate research findings for physicians, health
care providers, patients, payers, and policy makers," as well as "develop a
publicly available resources database that collects and contains governmentfunded evidence and research from public, private, not-for profit, and
academic sources."275 In addition, the OCKT must assist in the "timely
incorporation" of disseminated research findings into health information
technology ("HIT") clinical decision support tools. 2 76 The OCKT is also
responsible for creating a process to receive feedback from health care
providers, consumers, HIT vendors, and insurers on the value of the CER
information it disseminates.277 Meanwhile, AHRQ and the NIH have the
responsibility of training researchers to "build capacity" to conduct CER
that meets the methodological requirements of the PCORI. Additionally,
Congress instructed the Secretary of HHS to coordinate relevant federal
268.
269.
270.
271.
272.
273.
274.
275.
276.
277.

ACA § 6301(d) (to be codified at 42 U.S.C. § 1301)
Id.
Id.
Id.
Id.
Id.
ACA § 6301 (to be codified at 42 U.S.C. § 1320(e)).
Id.
Id.
Id.
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agencies in building CER data capacity, with the goal of creating and
maintaining a "comprehensive, interoperable data network to collect, link,
,,271
and analyze data on outcomes and effectiveness from multiple sources.
Unlike some provisions in the ACA,279 Congress fully appropriated funds
for the PCORI. Section 6301(d) orders a fund transfer from the Federal
Hospital Insurance Trust Fund2 80 and the Federal Supplementary Medical
Insurance Trust Fund281 to a "Patient-Centered Outcomes Research Trust
Fund."282 For fiscal year 2013, the PCORI will receive a dollar amount
equal to the average number of people "entitled to benefits" under Medicare
Part A, or enrolled in the Medicare Part B program.283 Then, in fiscal years
2014 through 2019, the PCORI will receive two dollars times the average
The statute also provides for an
number of these beneficiaries.284
adjustment in the event of an increase in national health expenditures.2 85 In
addition, Congress directly appropriated $10 million for fiscal year 2010,
$50 million for fiscal year 2011, and $150 million for fiscal year 2012.286
For fiscal years 2013 through 2019, the Institute will receive $150 million
plus the net revenues from an annual fee on health insurance and selfinsurance 2 87 plans. 2 88 Lastly, Congress established the PCORI as a taxexempt government corporation under section 501(1) of the Internal

Revenue Code. 289
The controversial political climate surrounding CER affected the
structure of PCORI in a number of ways. First, to address concerns that the
ACA's use of CER will mimic that of NICE in the United Kingdom, 290 the
278.
279.

Id.
See C. STEPHEN

REDHEAD ET AL., CONGRESSIONAL RESEARCH SERVICE,
DISCRETIONARY FUNDING IN THE PATIENT PROTECTION AND AFFORDABLE CARE ACT (2010)

(describing the provisions of the ACA for which Congress authorized, but did not
appropriate, funds).
280. ACA § 6301 (to be codified at 42 U.S.C. §1320(e)).
281. Id.
282. Id.
283. Id.
284. Id.
285. Id.
286. ACA § 630 1(e).
287. Self-insurance occurs when a (typically large) employer provides health
"insurance" for its employees by paying for their health care costs. Due to the Employee
Retirement Income Security Act ("ERISA"), self-insured employers avoid state insurance
regulations. See generally Jon R. Gabel et al, Self-Insurance In Times Of Growing And
Retreating Managed Care, 22 HEALTH AFF. 202, 202-04 (2003).
288. ACA § 6301(e)(1), 26 U.S.C.A. §4375(a) (2011). Section 6301(e)(2) imposes a fee
of two dollars multiplied by "the average number of lives covered under the policy," on each
insurance or self-insurance policy.
289. ACA § 6301(f), 26 U.S.C.A. §501(1) (2011).
290. Iglehart, supra note 61, at 1758 ("During US health care reform, QALYs quickly
became more code language for government-run health care systems and rationing.").
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PCORI is prohibited from using Quality Adjusted Life-Years ("QALYs") 29 1
"as a threshold to determine what type of health care is cost effective or
recommended. . . [or] to determine coverage, reimbursement, or incentive
programs."2 92 The statute also prohibits the Secretary of HHS from using
CER findings to make Medicare coverage decisions "in a manner that treats
extending the life of an elderly, disabled, or terminally ill individual as of
lower value than extending the life of an individual who is younger, nondisabled, or not terminally ill." 293 The Secretary of HHS also may not use
the findings "in a manner that precludes, or with the intent to discourage, an
individual from choosing a health care treatment based on how the
individual values the tradeoff between extending the length of their life and
the risk of disability." 294 Although Congress tempered these restrictions
with provisions that allow Medicare coverage determinations to be
informed by differences in comparative effectiveness between treatments
with regard to extending life due to "age, disability, or terminal illness" or
setting differential copayments "based on factors such as cost or type of
service,"295 the legislature clearly sought to send a strong message with
regard to limits on federal use of CER findings.
Second, to assuage fears about CER inhibiting medical treatment
innovation, 2 96 the 21-member board of PCORI must be filled with members
from a set of stakeholder interest groups, including industry and
researchers.297 Industry lobbyists also successfully persuaded Congress to
include a provision allowing the board to prohibit the agency from
contracting with a researcher for at least five years if research published
291. "A QALY gives an idea of how many extra months or years of life of a reasonable
quality a person might gain as a result of treatment." Measuring Effectiveness and Cost
Effectiveness: the QALY, NAT' INST. FOR HEALTH AND CLINICAL EXELLENCE,
http://www.nice.org.uk/newsroom/features/Measuring
effectivenessandcosteffectivenesstheqaly.jsp (last visited March 30, 2011). See generally
Peter J. Neumann & Dan Greenberg, Is The United States Ready For QALYs?, 28 HEALTH
AFF. 1366 (2009).
292. ACA § 6301(c), to be codified at 42 U.S.C. § 1320e-1(e).
293. Id.
294. Id.
295. Id.
296. Iglehart, supra note 61, at 1759.
297. ACA § 6301(f), 42 U.S.C.A § 1320e(f) (2011). The complete list of mandatory
stakeholder membership includes the Directors of AHRQ and the National Institutes of
Health ("NIH"), three representatives of health care consumers, seven representatives of
health care providers (including four physicians with at least one surgeon included in that
group, one nurse, one integrative health are practitioner, and a hospital), three representatives
of private payers (at least one representative of a health insurance issuer and one
representative of a self-insured employer), three representatives of the pharmaceutical,
device and diagnostic manufacturing industries, one representative of quality improvement
or independent health service researchers, and two representatives of the federal or state
governments, at least one of which must represent a federal health program or agency.
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under a previous contract with PCORI was not "within the bounds of and
entirely consistent with evidence and findings produced under the contract
with the Institute." 2 98 Congress, however, struck this section from the final
bill before it passed.299
Third, a coalition of unions and employee advocates persuaded Congress
to include a "real conflict of interest" disclosure requirement300 for PCORI
board members.30 ' Section 6301 includes two defined conflict of interest
terms. Under the statute, a "conflict of interest" is "an association,
including a financial or personal association, that [has] the potential to bias
or have the appearance of biasing an individual's decisions in matters
related to the Institute or the conduct of activities under" section 6301.302 In
contrast, a "real conflict of interest" is "any instance where a member of the
Board, the methodology committee ... or an advisory panel ... or a close
relative of such member, has received or could receive either ... a direct
financial benefit of any amount deriving from the result or findings of a
study conducted under" section 6301 or "a financial benefit from
individuals or companies that own or manufacture medical treatments,
services, or items to be studied. . . that in the aggregate exceeds $10,000
per year" including "honoraria, fees, stock, or other financial benefit and the
current value of the member or close relative's already existing stock
holdings, in addition to any direct financial benefit deriving from the results
or findings of a" PCORI study.30 3
Fourth, section 6301 includes rules of construction that make it clear the
Institute may not "mandate coverage, reimbursement, or other policies for
any public or private payer" or prevent "the Secretary [of HHS] from
covering the routine costs of clinical care received by" Medicare, Medicaid,
or CHIP beneficiaries.3 04 Further, the Secretary of HHS may only use the
PCORI's research findings to make Medicare coverage determinations after
an "iterative and transparent process which includes public comment and

298. Patient Protection and Affordable Care Act, Pub. L. No. 111-48, 124 Stat. 119 §
6301(d) (2010) (codified as amended at 42 U.S.C.A. § 1320e); see also Harry P. Selker &
Alastair J.J. Wood, Industry Influence on Comparative-Effectiveness Research Funded
through Health Care Reform, 361 NEw ENG. J. MED. 2595, 2596 (2009) ("To allow
scientists . . . to be punished for the publication of work that is not approved by this entity is
essentially to cede authority over the dissemination of government-funded research to a body
that is at least partially controlled by persons with a potential commercial interest in its
outcome.").
299. Patient Protection and Affordable Care Act, Pub. L. No. 111-48, 124 Stat. 119 §
10602(1)(B) (2010) (codified as amended at 42 U.S.C.A. § 1320e).
300. ACA § 6301(c), to be codified at 42 U.S.C. § 132 0e(f)(2).
301. Iglehart, supra note 61, at 1759-60.
302. ACA § 6301(a).
303. Id.
304. ACA § 6301(a).
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,,305

considers the effect on subpopulations,
and section 6301 does not alter
the coverage of "reasonable and necessary" treatments or allow the
Secretary to deny coverage "solely on the basis of' CER.306
In the fall of 2010, the Comptroller General appointed 19 members to the
PCORI Board. 307 The Board met once in 2010 and six times in 2011, with
plans to meet six times in 2012, in locations throughout the United States.
The PCORI has also established a Program Development Committee, 30 9 a
Public Affairs and Communications Committee, 310 and a Methodological
Committee.311 Thus, it remains too early to discern the agencies initial
actions and priorities, although the findings of the IOM and the Federal
Coordinating Council reports ordered by ARRA 3 12 may provide some
limited hints about the agency's future direction.
IV. OPPORTUNITIES AND CHALLENGES FOR THE FUTURE

Although the significant investments in CER included in ARRA and the
ACA present an important opportunity to facilitate CER through carefully
designed involvement by the federal government, the path forward is sure
to include a number of challenges. Some of those challenges are technical.
Existing CER infrastructure is fragmented,313 the government does not
currently have a database that would provide a systematic way for
researchers and the public to access federal CER studies, and it is not clear
how many studies exist. 3 14 Commentators have called for the creation of a
universal, standardized database to include all clinical trial and research
data sets, including a rapid-learning, open database for CER studies, 315 and
305. ACA § 6301(c).
306. Id.
307. For the current membership of the Board, see Current Membership of the PatientCentered Outcomes Research Institute (PCORI) Governing Board, U.S. Gov'T
ACCOUNTABILITY OFFICE, http://www.gao.gov/about/hcac/pcori members.html (last visited
March 30, 2011).
308. See Past Meetings and Events, PCORI, http://www.pcori.org/meetings-events/pastmeetings-events/ (last visited Jan 15, 2012).
309. See PROGRAM DEVELOPMENT COMMITTEE, REPORT TO PCORI (2011), availableat
http://pcori.org/images/PDC Report 03-07-2011 .pdf.
310. See PUBLIC AFFAIRS AND COMMUNICATIONS COMMITTEE REPORT (2011), available
at http://www.pcori.org/images/PACCReport 03-08-2011 .pdf
311. See REPORT FROM THE METHODOLOGY COMMITTEE TO THE BOARD OF GOVERNORS
(2011), availableat http://www.pcori.org/images/MCReport_03-08-2011 .pdf.
312. See supra section 111(b)(2).
313. See FEDERAL COORDINATING COUNCIL FOR COMPARATIVE EFFECTIVENESS
RESEARCH, supra note 11, at 33.
314. Id. at 29 (noting that while AHRQ tracks its funding and studies, there is no
standard way to identify CER funded through the NIH). For a chart of existing research
"person-level" research databases within the federal government, see id. at 64-68.
315. Etheredge, supra note 103, at 1763-1764.
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a National Patient Library to make available to the public the results of
federally funded CER.316 A clearinghouse for information about federal
investment in CER would be helpful to ensure that spending matches
identified priorities and goals. 1
Regardless of its form, some sort of
centralized database that organizes and provides access to information
about sponsored CER studies and their results will be a necessary first step
toward measuring the success of the government's initiatives and
disseminating research results.
Other challenges will be methodological and evidentiary. Although the
ACA requires the PCORI's methodological standard to "provide specific
criteria for internal validity, generalizability, feasibility, and timeliness,"
this standard governs the research and analysis itself.3
In contrast, an
evidentiary standard would govern the decision about what type of study
(such as a controlled trial) to require of sponsored studies. 319 Because there
are several ways to conduct CER, including systematic reviews of existing
evidence, meta-analyses, experimental studies (including randomized
control trials), and non-experimental studies (including retrospective and
prospective observational studies),3 20 this is not a simple decision.32'
Although randomized clinical trials are the most rigorous form of research,
they are expensive and time consuming, and their traditional form may
require some modification to become more suitable for CER. 322 In addition,
it will be necessary to establish realistic expectations for the timeline and
costs of CER, regardless of which research methods the PCORI endorses.
Because CER studies may need to have large sample sizes in order to
produce significant results about different types of patients, and it may take
a long time to fully observe important long-term outcomes, CER may be

316. Jeffrey C. Lerner et al., The Case ForA NationalPatient Library, 29 HEALTH AFF.
1914 (2010).
317. Benner, supra note 234, at 1774.
318. Garrison et al., supra note 15, at 1816.
319. Id. For a general overview of some methods of conducting CER, see 2007 CBO
REPORT, supra note 47, at 20-25.

320. Nancy A. Dreyer et al., Why ObservationalStudies Should Be Among The Tools
Used In ComparativeEffectiveness Research, 29 HEALTH AFF. 1818, 1818 (2010).
321. See id. at 1820-22 (proposing "criteria for determining which type of study to
employ" in different circumstances); see also Rachael L. Fleurence at al., The CriticalRole
Of ObservationalEvidence In Comparative Effectiveness Research, 29 HEALTH AFF. 1826
(2010) (comparing the benefits and flaws in observational studies and randomized trials);
Elshaug & Garber, supra note 48, at 1392 (noting that well-designed observational studies
have potential to generate information about subgroups excluded from clinical trials,
although randomized trials remain important under certain circumstances).
322. See generally Bryan R. Luce et al., Rethinking Randomized Clinical Trials for
Comparative Effectiveness Research: The Need for TransformationalChange, 151 ANNALS
INTERNAL MED. 206 (2009).
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more costly and time-consuming than other forms of research.323 In order
to fully evaluate the success of the PCORI, it will be important to balance
the need for aggressive efforts to generate research findings as quickly as
possible with realistic expectations about the time needed to achieve high
quality results.
The PCORI, and the range of entities that are likely to use its research,
will also have to decide whether to set an evidentiary standard for
sponsored CER. The FDA, for example, requires "substantial evidence,"
typically based on at least two major double-blind and randomized trials (or
one with supporting evidence in some circumstances) to approve a new
drug or biological,324 and a similar standard applies to comparativeeffectiveness claims about such products.325 In practice, the applicable
evidentiary standard depends on "the novelty of the product, the medical
need for new therapies for the target condition, and what is known about the
product's effectiveness relative to its risks," with lower standards applied to
treatments that have potential to serve an important unmet need, and higher
standards applied to products that seem comparable to approved products or
that have an uncertain safety profile. 326 Even for agencies like the FDA,
however, that have relatively strict and clear evidentiary standards, expert
judgment is still used to evaluate the evidence.327 One set of authors has
recommended that the PCORI qualify its research by describing its "relative
value" based on an estimation of the value of more research on the
subject.32 8 Regardless of what standard that the PCORI adopts, the use of a
consistent measure qualifying the strength of new evidence would bolster
the credibility of research findings disseminated by the new agency.329
Such a standard would assist providers and consumers in evaluating
323.

MCCLELLAN &BENNER, supra note 17, at 9.

324. Garrison et al., supra note 15, at 1813.
325. See 21 C.F.R. § 202.1(e)(6)(ii) (defining false and misleading advertisements to
include comparative claims not supported by "substantial evidence" or "substantial clinical
experience"); see also 21 U.S.C. § 355(d) (2006) (section 505 of the Food Drug and
Cosmetic Act, which defines "substantial evidence" as "evidence consisting of adequate and
well-controlled investigations, including clinical investigations, by experts qualified by
scientific training and experience to evaluate the effectiveness of the drug involved, on the
basis of which it could fairly and responsibly be concluded by such experts that the drug will
have the effect it purports or is represented to have under the conditions of use prescribed,
recommended, or suggested in the labeling or proposed labeling thereof'); 21 C.F.R. §
314.126 (defining "adequate and well-controlled studies" for the purpose of determining
whether a claim of efficacy is supported by "substantial evidence" under section 505 of the
Food, Drug and Cosmetic Act); 21 C.F.R. § 202.1(e)(4)(ii)(c) (defining "substantial clinical
experience").
326. Garrison et al., supra note 15, at 1814.
327. Id. at 1815.
328. Id. at 1814.
329. See Cynthia D. Mulrow & Kathleen N. Lohr, Proof and Policy from Medical
Research Evidence, 26 J. HEALTH POL., POL'Y &L. 249, 254-59 (2001).
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whether to change their current practices, and would provide important
context for the new findings.
An additional issue facing the PCORI and other efforts to expand CER is
research capacity. A recent study found that the United States has "little or
no excess capacity" to conduct additional clinical trials, based on
constraints in the supply of both patients and investigators.3 30 Thus, any
expansion in clinical trial-based CER is likely to require the diversion of
resources from other research, expanded research capacity through
improved efficiency, or increased incentives for investigators and
participants to engage in CER.3 3 1 Existing health information privacy rules
are also likely to make it difficult to conduct CER using existing patient
data (for example, information included in electronic health records),332
although some databases of patient-level information for observational
studies do exist.3 33 In this way, evolving privacy rules and standards for the
use of patient information aggregated through health information
technology will play a key role in the future of CER.
Realizing the much-touted benefits of CER, including cost control,334
through widespread adoption of the research's results by health care
providers and consumers will likely present the most difficult challenges.3 35
330. Robert B. Griffin & Janet Woodcock, Comparative Effectiveness Research: Who
Will Do The Studies, 29 HEALTH AFF. 2075, 2076, 2078 (2010) (arguing for the creation of a
"federally funded national research infrastructure" that would "provide a mechanism for
community-based clinicians to participate in clinical trials" in a less burdensome way and
would "reduce the redundancy and inefficiency intrinsic to the 'cottage industry' nature of
the clinical research process.").
331. Id.
332. See generally Douglas Peddicord et al., A Proposal To Protect Privacy Of Health
Information While Accelerating Comparative Effectiveness Research, 29 HEALTH AFF. 2082
(2010).
333. See, e.g., Wilson D. Pace et al., An Electronic Practice-BasedNetwork for
Observational Comparative Effectiveness Research, 151 ANNALS INTERNAL MED. 338

(2009) (describing the AHRQ-funded Distributed Ambulatory Research in Therapeutics
Network).
334.

See MCCLELLAN AND BENNER, supra note 17, at 14 (linking cost control with goals

of conducting "high value" research, developing a "robust research infrastructure," and
creating mechanisms "to promote the appropriate use of new evidence in clinical practice
and health policy in a timely way").
335. In the face of this problem, a new field, "implementation science," the study of
methods to promote incorporation of research findings and evidence-based medicine into
real-world practice, has emerged. See generally Ann C. Bonham & Mildred Z. Solomon,
Moving Comparative Effectiveness Research Into Practice:Implementation Science And The
Role Of Academic Medicine, 29 HEALTH AFF. 1901, 1902-03 (2010). Early information
from this science suggests four important considerations for the purpose of information
dissemination: "the characteristics of the intervention will influence whether clinicians and
patients adopt and sustain a new practice. . . . the mind-set of people who are expected to
implement the new practice is critical .

..

. the context in which clinicians practice shapes

their willingness and ability to adopt new practices . . . [and] the process by which change is
implemented can determine whether it is successful." See David Atkins et al., The Veterans
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Although some federal agencies that conducted CER before ARRA and the
ACA have sought to translate their studies into usable information for
health care patients and providers,3 36 outside of the agencies that conduct
research in connection with directly providing care (like the VHA),n
dissemination and adoption remain challenging.338
In order to ensure that the results of subsidized comparative effectiveness
studies reach their target audiences, it is important to incorporate
dissemination plans into study design. 3 39 Furthermore, to permanently
improve channels for the diffusion of new comparative effectiveness
information, it may also be helpful to improve continuing education
programs for health care providers,3 4 0 to incorporate the information into
health information technology systems, 34 1 and to address marketing for
medical treatments. 3 42 As discussed above, a publicly available library of
CER results could also assist in disseminating new information to health
care providers and consumers. 3 43 Regardless of how the PCORI or other
entities seek to diffuse CER information, however, it is crucial that the
information disseminated is relevant to the needs of consumers and
Affairs Experience: Comparative Effectiveness Research In A Large Health System, 29
HEALTH AFF. 1906, 1908 (2010). Thus, factors including the strength of the evidence, its
degree of "relative advantage" in terms of time, ease, or profitability, local culture, patient
expectations, support for providers changing practice, and the use of a consensus-building
process can affect the adoption of the information. Id. "Making it easy to do the right thing"
thus becomes critically important. Id at 1911. See also Naik & Petersen, supra note 198, at
1931 (calling for an "implementation research and development program" to "accelerate the
translation of evidence into everyday care, enhance the opportunities for doctors and patients
to define value . .. on the basis of their understanding of local contexts and constraints, and
allow providers and patients to communicate with researchers and policymakers about
clinically important issues earlier in the research process.").
336. For example, AHRQ publishes a number of guides on its website that provide
summaries of, and recommendations related to, CER studies, and also partners with
professional societies, non-profit organizations, and patient advocacy groups to disseminate
its findings.

See FEDERAL COORDINATING COUNCIL FOR COMPARATIVE EFFECTIVENESS

RESEARCH, supra note 11, at 35.
337. Id; see, e.g., Comparing Medical Treatments, AGENCY FOR HEALTHCARE
RESEARCH AND QUALITY, http://www.ahrq.gov/consumer/compare.html (last visited March

30, 2011). The Center
Mental Health Services
Office of the National
Resources and Services

for Disease Control ("CDC"), the DoD, the Substance Abuse and
Administration, the FDA, the Office of Public Health and Science,
Coordinator for Health Information Technology, and the Health
Administration are also involved, to various degrees, in efforts to

disseminate research findings. See FEDERAL COORDINATING COUNCIL FOR COMPARATIVE
EFFECTIVENESS RESEARCH, supra note 11 , at 36-38.

338. See, e.g., supra notes 194-198 and accompanying text.
339. Avorn & Fischer, supra note 23, at 1895.
340. See Bonham and Solomon, supra note 335, at 1903 (advocating for academic
medicine to play an active role in pushing for the dissemination of CER results).
341. Atkins, supra note 335, at 1908.
342. Avorn & Fischer, supra note 23, at 1896.
343. See Lemer, supra note 316.
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providers, in terms of its applicable populations and settings, its comparison
to relevant alternative treatments, and its consideration of patient
preferences. 3 4 4 It is also likely to be much easier to diffuse CER results
when those results are published before widespread adoption of a new
technology, 345 So it will be important for the PCORI to time its studies of
new technologies aggressively.
In addition to delays associated with inertia and challenges associated
with disseminating information among a large and diverse population, to
the extent that economic incentives either discourage or do not facilitate
rapid adoption, diffusion will be all the more difficult. Economic incentives
favoring the diffusion of CER findings could derive from the inclusion of
research findings in private insurance coverage design 34 6 or through
incorporation into the Medicare or Medicaid coverage rules. 34 7 Because the
ACA includes strict limits on how the Secretary of HHS may use CER to
inform Medicare coverage for specific treatments,34 8 however, widespread
consideration of CER results in insurance coverage design may proceed
more slowly than if Medicare were to have greater authority.
Even before the passage of the ACA, the structure of Medicare (and
Medicaid, to a lesser extent) was not conducive to the inclusion of CER in
Medicare is statutorily required to cover only
coverage decisions.
"reasonable and necessary" treatments, 3 49 a standard which does necessarily
344. See Atkins, supra note 335, at 1907-08.
345. Alexander and Stafford, supra note 16, at 2488; see also Elshaug and Garber, supra
note 48, at 1392.
346. See generally James C. Robinson, Comparative Effectiveness Research: From
ClinicalInformation To Economic Incentives, 29 HEALTH AFF. 1788 (2010) (describing the
mechanisms by which private insurers could incorporate CER into their plans).
347. See Steven D. Pearson and Peter B. Bach, How Medicare Could Use Comparative
Effectiveness Research In Deciding On New Coverage And Reimbursement, 29 HEALTH AFF.
1796 (2010).
348. ACA § 6301(c). Notably, the statute "does not discourage researchers from
measuring QALYs or other comprehensive health outcome metrics." Garber & Sox, supra
note 68, at 1807.
349. Social Security Act § 1862, codified at 42 U.S.C. § 1395y(a) (2006). The test used
in local coverage determinations asks whether a treatment is: (1) "safe and effective; (2) not
experimental or investigational;" and (3) "appropriate" (i.e. "furnished in accordance with
accepted standards of medical practice, furnished in an appropriate setting, ordered or
furnished by qualified personnel, able to meet but ..not exceed, the patient's medical needs,
[and] at least as beneficial as an existing and available medically appropriate alternative."
JOST, supra note 167, at 212. In theory, these decisions are supposed to be based on
published studies that included randomized control trials or "other definitive study
methodologies," but in practice, factors such as the medical standard of care and consensus
play a role when such studies are not available. Id. at 212-213. CMS uses a different
process for national coverage decisions, but this process lacks clear written criteria. Id. at
214-219. See generally Fox, supra note 36 (criticizing the national coverage decision
process); see also id. at 8 (noting that although CMS does not have authority to decline to
cover a treatment due to its cost, the fact that Medicare operates within a budget set by
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include comparative or cost effectiveness information.5 o An effort in 2000
to publish a rule that would require new covered treatments to "add value"
failed.3 1 Furthermore, most Medicare coverage decisions are made on a
local level,352 and because of the program's prospective payment system,
Medicare does not make an explicit coverage determination for most
treatments.35 3 In combination with the fact that Medicare payment rates for
a given treatment are roughly cost-based,35 4 use of CER by CMS to create
economic incentives favoring evidence-based care is quite limited. 355
Thus, when the existing Medicare coverage regime is combined with the
limits created by the ACA, it becomes clear that a fundamental redesign
would be necessary to fully encourage and support use of comparative
effectiveness information by health care providers who participate in the
Medicare program.35 6 Because of the roles states play in administering the
Medicaid program, universal incorporation of CER results into that
program would be complex as well. 35 7 At least in the near term, the lack of
political will for such redesign is likely to be a barrier. A 2010 public
opinion poll found that while Americans strongly support use of CER to
provide additional information to support medical decision-making, only
approximately half of those polled supported use of comparativeeffectiveness information to determine public and private insurance
coverage for treatments.
Additionally, more than sixty percent of
respondents opposed using the information to charge patients more for
choosing treatments found to be comparatively ineffective.358
In
combination with a 2009 poll in which respondents found arguments
Congress and Congress must raise revenue to cover increased costs "creates an incentive for
CMS to control cost without appearing to violate the law, and provides Congress with an
incentive to loosely examine CMS's cost-saving decisions").
350. Pearson & Bach, supra note 347, at 1196-97 (noting the fragmented ways by which
the federal government makes Medicare coverage decisions: a single national decision, "a
series of separate determinations made by the medical directors of independent contractors in
different regions of the country," through a Congressional mandate, or by non-governmental
third parties).
351. 2007 CBO REPORT, supra note 47, at 31-32.
352. See generallyJOST, supra note 167, at 212-213.
353. See generally id. at 210.
354. Pearson & Bach, supra note 347, at 1798.
355. See id at 1797-1798 (describing Medicare "coverage" and "reimbursement" as
"separate silos" that "demonstrate the arcane complexity of decades of ad hoc updates with
no fundamental redesign.").
356. See, e.g., id. at 1798-1800 (proposing a reform to Medicare whereby coverage and
reimbursement determinations would be made based on categorizing a new treatment as
having "superior effectiveness," "comparable effectiveness" or "insufficient evidence"); see
also 2007 CBO REPORT, supra note 47, at 31; Orszag, supra note 90, at 18-19.
357. Id. at 19-20.
358. Alan S. Gerber et al., The Public Wants Information, Not Board Mandates, From
ComparativeEffectiveness Research, 29 HEALTH AFF. 1872, 1874-75 (2010).

http://lawecommons.luc.edu/annals/vol21/iss2/4

50

Francis: Beyond Safe and Effective: The Role of the Federal Government in

2012]

Beyond "Safe and Effective"

379

against the use of evidence-based treatment guidelines to be more
persuasive than arguments in favor of the guidelines,359 this underscores the
reality that even though the PCORI survived the political battle over the
ACA, political challenges are likely to play a continuing role in the use of
CER resulting from the law.
Furthermore, even if the federal government found a politically feasible
way to tie Medicare reimbursement with the findings of CER, it is far from
clear that this would result in overall cost savings in the program. Due to
the ability of health care providers to offset decreases in fees through
increased volume, known as "supplier induced demand" or the "volume
response hypothesis," 360 savings resulting from CER might be offset by
increased expenditures in other areas. 36 1 Even absent this effect, it can take
a long time to conduct, analyze, and disseminate the findings of CER, and
any significant cost savings resulting from CER are likely to be at least a
decade away.362 Thus, political support for the research is likely to unravel
if solely based on the prospect of cost savings, and particularly near-term
cost savings. Yet, based on the experiences of the governments of other
countries that have funded CER,36 3 if the PCORI survives, pressure may
mount for the agency to explicitly consider cost information in addition to
comparative effectiveness.
As was seen in the controversy surrounding the AHCPR in the 1990s, 3 64
any attempt to combine health care research and policy efforts can be
politically hazardous. While the ACA ostensibly did not provide the
PCORI with general policymaking authority, the inherent policy
359. Alan S. Gerber et al., A National Survey Reveals Public Skepticism About
Research-based Treatment Guidelines, 29 HEALTH AFF. 1882 (2010) (finding that the most
support for the statement that "no outside group should come between doctors and patients in
making treatment decisions").
360. See generally Morris L. Barer et al., Fee Controls as Cost Control: Tales from the
Frozen North, 66 MILIBANK Q. 1, 38-46 (1988); see also Miriam J. Laugesen, Siren Song:
Physicians, Congress, and Medicare Fees, 34 J. HEALTH POL., POL'Y & L. 157, 162-64
(2009) (describing the historical interaction between this characteristic of physician
reimbursement and Medicare policy).
361. See also Elshaug and Garber, supra note 48, at 1392 (noting that some of the
savings associated with CER might be reduced if providers replace discredited treatments
with other costly treatments).
362. 2007 CBO REPORT, supra note 47, at 30; see also Orszag, supra note 90, at 16
("Getting to the point where additional research on comparative effectiveness could have a
noticeable impact on health spending would itself take several years. . . . Initially, the
available results would probably address a relative small number of medical treatments and
procedures; additional time would have to elapse before a substantial body of results
amassed. And in areas of medicine that involve significant levels of spending, several
studies could be needed before a consensus emerged about the appropriate conclusions to be
drawn - even if those studies did not generate conflicting results.").
363. See supra note 158 and accompanying text.
364. See supra notes 172-182 and accompanying text.
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implications of CER that pervade section 6301 suggest that the PCORI may
face similar challenges. Observers have noted that the AHCPR faced
political opposition both because of a high risk that it would fail to meet
high, and "arguably naive," expectations, and because it tackled issues
related to the distribution of health care dollars, which created political
Moreover, close identification with a
enemies of the endeavor.3 65
president's health policy agenda, while demonstrating an agency's
relevance, can also foster political opposition. 36 6 Lastly, in order for a
health research agency to remain viable, it must have a relatively stable
constituency of supporters to lobby the political branches on its behalf.
This is challenging for forms of research, like CER, that are not well
understood and do not necessarily have as discrete a group of supporters as,
for example, cancer research conducted through the NIH.367
The PCORI is likely to encounter these same problems. While
proponents of CER are right to point to the research's vast potential to
improve health care quality and perhaps lower costs, achieving those goals
is sure to be challenging. Particularly with regard to CER's potential to
lower costs, it is naive to imagine that the PCORI, or any other public or
private entity, will alone be able to offer a solution when so many others
have failed. Health care cost control is a distributional issue, and in order to
save taxpayers and private payers money, someone, whether drug and
device manufacturers, physicians, hospitals, or insurance companies, will
have to lose future earnings.368 This problem is exacerbated by the fact that
the benefits of CER reach the entire population, while the costs are highly
Thus, if
concentrated among a discrete group of stakeholders. 3 69
policymakers lack the political will to resist pressure from powerful
financial stakeholders, there is little reason to imagine that the PCORI's
research will have much cost-saving effect. Yet, because of the lofty
expectations placed upon the agency and the idea of CER, this failure is
likely to contribute to political arguments against the PCORI. Thus, CER
proponent's unrealistic claims about the research's potential may not be
doing the issue any favors. Furthermore, the fact that the PCORI will be
closely tied, at least for the foreseeable future, with a controversial health
reform law, is also likely to contribute to the agency's political fragility.
It is worth re-emphasizing that the survival of the PCORI hinges on its
ability to achieve the overt support of those who have potential to benefit
365.
366.
367.
368.

Gray, supra note 175, at 304.
Id. at 304-305.
See id. at 305.
See Eugene C. Rich, The Policy Debate over Public Investment in Comparative

Effectiveness Research, J. GEN. INTERNAL MED. 752, 753 (2009).

369.

See Theodore R. Marmor et al., The Politics ofMedical Inflation, 1 J. HEALTH POL.,

POL'Y & L. 69, 73-74 (1976).

http://lawecommons.luc.edu/annals/vol21/iss2/4

52

Francis: Beyond Safe and Effective: The Role of the Federal Government in

2012]

Beyond "Safe and Effective"

381

from its research, which is anyone who uses health care products and
services. To reach these constituents, however, the agency will have to
expand public understanding of CER, as well as work to dispel fears about
the research interfering with the physician-patient relationship or unduly
influencing insurance benefits. But, even if the PCORI is successful in
increasing its public support, it is unclear whether any level of broad public
support could overcome the concentrated opposition of a smaller group of
financial stakeholders. The results of the PCORI's CER studies thus may
not be enough to have a significant impact on rising health care costs in the
United States absent additional major reform of the health care system.
The arguments in favor of government support for CER are robust.
While private efforts to compare medical treatments are important and
should be encouraged, there is little evidence to suggest that the private
sector alone is well suited to meet the informational needs of the health care
system as a whole. Not only are private efforts likely to be fragmented,
duplicative and of limited accessibility to the general public,37 0 they have so
far left most medical treatments unevaluated.37 1 In reality, CER is a public
good for which the government can play an important role in increasing to
an efficient level.372
Yet, some criticisms of CER have served a constructive purpose in
ensuring that advocates are not blind to problems associated with the
research. Concerns about the interaction between CER and personalized
medicine,373 for example, may have contributed to the ACA's conception of
the research as helping to identify which treatments work best for which
groups of patients under which circumstances, rather than pure head-tohead comparisons that may miss important nuances in treatment
suitability. 374 Moreover, while it can be frustrating for those who believe in
the potential of CER to control costs that Congress has imposed such high
barriers to the incorporation of research findings into the design of public
insurance programs, those barriers may serve to decrease the harm that
might be caused by premature adoption of uncertain research findings."
Finally, in the words of former Congressional Budget Office Director Peter
370. Wilensky, supra note 82, at w722.
371. See supra note 90.
372. See supra notes 82-87 and accompanying text.
373. See supra notes 33-34.
374. Cf Fox, supra note 36, at 34-36 ("CER can be useful, but it is extremely complex
and potentially problematic to implement recommendations based on its results. CER's
usefulness depends on a fairly sophisticated level of understanding regarding the meaning of
its results and how to use that information. It may be that this complexity is what raises such
significant public concerns. . . . The challenge with the information available from CER is to
resist over-simplifying, that is, reaching for an easy decision about medical treatments when
the data alone does not justify that response.").
375. See supra notes 39-41 and accompanying text.
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Orszag, "moving the nation toward" a future of lower health care costs and
better outcomes "will inevitably be an iterative process in which policy
steps are tried, evaluated, and reconsidered."3 76 Thoughtful analysis and
criticism of the government's CER endeavors plays an important role in
that process.
Ultimately, perhaps the most valuable aspect of the federal government's
recent investment in CER is its potential to alter the norms surrounding
medical innovation. While innovation in medical treatments is crucially
important to efforts to improve both health and health care services in the
United States, innovation itself has no inherent value. Rather, the value of
medical innovation comes from its ability to offer improvement relative to
the status quo.377 Of course, some failure, both in the form of treatments
that do not work and treatments that are less effective than alternatives, is
inherent to the process of medical innovation. The answer to that aspect of
innovation is not to allow less effective innovations to indefinitely remain
part of standard medical practice. It is imperative that we continuously
study and refine our ideas about which treatments work best under what
circumstances, and then to act on that knowledge.
Thus, rightly or wrongly, the number of drugs and devices that can meet
the FDA's market entry requirements provides an incomplete picture of the
state of medical innovation. It also fails to incentivize the type of
innovation that will move health care in the United States forward. In this
way, even if the PCORI is unable to unilaterally transform the United States
health care system by enforcing adherence to evidence-based best practices,
it may succeed in transforming and improving the standards to which new
medical treatments are held, even if the new standards are not firmly
binding. To the extent that individuals and institutions are willing to use
the data and information provided by the PCORI to hold medicine to
standards that are both higher and better aligned with patient interests, the
ACA's experiment with enhanced federal support for CER will have been a
success.

376.
377.

Orszag, supra note 90, at 2.
Cf Sean Palfrey, Daringto PracticeLow-Cost Medicine in a High-Tech Era, 364

NEw ENG. J. MED. e21(1) (2011).
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